WO2002002530A1 - Antagoniste de gpr14 - Google Patents
Antagoniste de gpr14 Download PDFInfo
- Publication number
- WO2002002530A1 WO2002002530A1 PCT/JP2001/005784 JP0105784W WO0202530A1 WO 2002002530 A1 WO2002002530 A1 WO 2002002530A1 JP 0105784 W JP0105784 W JP 0105784W WO 0202530 A1 WO0202530 A1 WO 0202530A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- substituted
- atom
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a novel GPR14 antagonist and a novel benzoxazepine derivative having GPR14 antagonistic activity or a salt thereof.
- Perotinsin II was discovered as one of the potent vasoconstrictor peptide hormones and has a vasoconstriction far superior to endothelin, the most potent vasoconstrictor currently known for mammalian arteries It is clear that It has also been clarified that the receptor for perotinsin II is the GPR14 protein, one of the orphan receptors. [Nature, 401, 282 (1999)].
- benzozepine derivatives include, for example, E P—A—487071, E
- P-A-560235 discloses a conjugate useful as an acetylcholinesterase inhibitor
- W098 / 46590, WOO 0/23437 discloses compounds useful as an anti-obesity agent.
- GPR14 antagonists which are receptors for perotinsin II, are expected to be developed as new vasoactive drugs (eg, therapeutic agents for ischemic myocardial infarction, congestive heart failure, etc.). No reports have been reported yet.
- the present invention provides a vasoactive agent, particularly a vasoconstriction inhibitor, which is useful as a therapeutic agent for the prevention of hypertension, arteriosclerosis, cardiac hypertrophy, cardiac myocardial infarction, heart failure, etc., based on GPR14 antagonism;
- the present invention provides a novel benzozepine derivative having the following or a salt thereof.
- the present inventors have conducted intensive studies on compounds having GPR14 antagonistic activity, and as a result, have found that a compound represented by the following formula (I) or a salt thereof (hereinafter, referred to as compound (I) It has been found that the compound exhibits excellent GPR 14 antagonistic activity, and based on this, has completed the present invention. That is, the present invention
- Ar represents an aryl group which may be substituted
- X represents a spacer having 1 to 4 atoms constituting the straight-chain portion
- n represents an integer of 1 to 10.
- R is a hydrogen atom or a hydrocarbon group which may be substituted, and may be the same or different in repeating n, and R is a ring bonded to Ar or a substituent of Ar.
- Y represents an amino group which may be substituted or a nitrogen-containing heterocyclic group which may be substituted.
- R 1 1 represents a hydrogen atom or an optionally substituted hydrocarbon group
- X a represents a spacer having 1 to 12 number of atoms constituting the straight chain moiety, R 1 1 and X a may combine to form a ring
- a a represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group
- R 12 represents a substituted
- R 13 represents an optionally substituted hydrocarbon group or an optionally substituted hydrocarbon group
- R 13 represents an optionally substituted hydrocarbon group
- the Ba ring and the Ca ring are each further substituted.
- GPR14 antagonist comprising a compound represented by the formula or a salt thereof; (2) The agent according to the above (1), wherein Ar is an optionally substituted phenyl group;
- R 1 is (1) a hydrogen atom
- heterocyclic group nitrogen A monocyclic or 2- to 4-cyclic heterocyclic group containing 1 to 6 heteroatoms selected from atoms, oxygen atoms and sulfur atoms
- the heterocyclic group is (i ') a halogen atom, (ii ') a nitro group, (iii') Shiano group, (iv) Okiso group, ([nu ') hydroxy group, (vi') - 6 ⁇ alkyl group, (vii,) C 1 _ 6 alkoxy group, (viii ') C 1 _ 6 alkylthio group, (ix) amino group, (X) mono- 6 alkylamino group, (xi,) g
- guanidino group (this guanidino group may be mono- or di-substituted with a 6- alkyl group), (XXX) pyrrolidinocarbonyl, piperidinocarbonyl, (4-methylbiperidino) carbol, (4 -Fenrubiperidino) carbonyl,
- Substituent 1 to 5 has optionally may linear even or branched to - 6 alkyl group, a linear or branched C 2 _ 6 alkenyl group, a linear or branched C 2 _ 6 ⁇ Rukiniru group, C 3 _ 6 cycloalkyl group, a crosslinked cyclic C 8 - x 4 saturated hydrocarbon groups, C 6 - E 4 Ariru group, C 7 _ 1 6 Ararukiru group, C 6 _! 4 reel one C 2 _!
- Ring A further contains (i) an amino group, (ii) a mono-- 6 alkylamino group, (iii) a di-- 6 alkylamino group, and (iv) a nitrogen atom, an oxygen atom and an oxygen atom in addition to one nitrogen atom.
- a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from sulfur atoms, (V) di- 6- alkyl monopropanolamino group, (vi) aminocarboxy-oxy group, ( vii) mono- 6- alkylamino-carboxyloxy group, (viii) di- 6- alkylamino-carbonyloxy group, (ix) C 1 - 6 alkyl sulfo - Ruamino group, (X) phenylene Roux - 6 alkyl Ruamino, (xi) phenyl one C _ 6 alkyl one sulfo - Ruamino group, (xii) Hue - Le sulfonyl ⁇ amino group, have a 6 alkyl group, and (XV) halogenated substituent selected from optionally C 1 _ 6 alkoxy group optionally - (xiii) halogen atom, (xiv) an optionally halogenated
- R 1 is (1) a hydrogen atom
- XXIV a carboxyl- 6 alkyl group
- XXV a monocyclic or 2-cyclic hetero atom containing 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom And a tetracyclic heterocyclic group
- the heterocyclic group includes (i,) a halogen atom, (ii,) a nitro group
- guanidino group (this guanidino group may be mono- or di-substituted with 1 to 6 alkyl groups), (XXX) pyrrolidino-potassium, piperidino-potassium, (4-methylbiperidino) carbo- Le, (4-phenyl-biperidino) carbonyl,
- ( ⁇ ′) a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon and one nitrogen atom, (xiii ') C 1 _ 6 alkyl one carbonyl ⁇ amino group, (xiv') C _ 6 ⁇ Ruki Lou sulfonyl ⁇ amino group, (xv one C 1 one 6 alkoxy one carbonylation Honoré group,
- the A ring further has (i) an amino group and (ii) a mono. - 6 alkylamino group, (iii) Di- 6 alkylamino group, (iv) one or three nitrogen atoms, optionally having one to three heteroatoms selected from nitrogen, oxygen and sulfur atoms, 5 to 7 members A cyclic amino group, (V) a C x _ 6 alkyl mono-propionylamino group, (vi) an aminocarponyloxy group, and (vii) a mono-. (Viii) alkylamino-carboxyloxy group; _ 6 alkylamino-carbonyloxy group,
- the agent according to the above (1) which is a group represented by the formula:
- R 3 a and R 3 b are each independently a hydrogen atom, Shiano group, hydroxy group, amino group, C 1 - shows a 6 alkoxy group - 6 alkyl group or a.
- the agent according to the above (1) which is a group represented by the formula:
- X is - CO-, One 0_, -S0 2 one, one SO 2 NR 3 a primary, -CR 3 a (R
- R 3 a and R 3 b are each a hydrogen atom, Shiano group, hydroxy group, amino group, C, or _ 6 alkyl group - - 3 b) one or a CONR 3 a 6 alkoxy
- the agent according to the above (5) which is a group represented by the formula:
- X gar CONR 3 a - (wherein, R 3 a is a hydrogen atom, Shiano group, hydroxy sheet group, an amino group, C: _ 6 represents an alkyl group or a 6 alkoxy groups) are tables in The agent according to the above (5), which is a group;
- R 2 is (1) a hydrogen atom
- R 2 c and R 3 are the same or (I) hydrogen atom, (ii) ( ⁇ ') halogen atom, ( ⁇ ') nitro group, (iii ') cyano group, (iv') oxo group, ( ⁇ ') hydroxy group, ( ⁇ ') C 1 _ 6 alkyl group (this - 6 alkyl group may be substituted by phenyl),
- ( ⁇ ′) a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom in addition to a carbon atom and one nitrogen atom, (xiii ′ ) C 1 _ 6 alkyl one carbonyl ⁇ amino group, ( ⁇ ') - 6 ⁇ alkyl one Suruhoniruamino group, ( ⁇ ') C 1 - 6 alkoxy one carbonyl group,
- substituent C group and abbreviated force al chosen substituent 1 to 5 have they may be straight-chain or branched - 6 alkyl group, a linear or branched C 2 - 6 alkenyl group , linear or branched C 2 one 6 alkynyl group, C 3 one 6 cycloalkyl group, a crosslinked cyclic C 8 -, 4 saturated hydrocarbon groups, C 6 - i 4 Ari le group, C 7 - 6 Aralkyl group, C 6 — 4 aryl group C 2 — 12 alkenyl group,
- the heterocyclic group is the same as the above-mentioned substituent group C R 2 c and R 30 may be bonded to each other and have a substituent together with an adjacent nitrogen atom.
- a nitrogen-containing saturated heterocyclic group (the nitrogen-containing saturated heterocyclic group may have 1 to 5 substituents selected from the above-mentioned substituent group C).
- xii a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom in addition to a carbon atom and one nitrogen atom, (xiii) C 1 _ 6 alkyl - carbonyl ⁇ amino group, (xiv) C, _ 6 alkynyl Lou sulfonyl ⁇ amino group, (xv) C 1 _ 6 alkoxy one carbonyl group, (xvi) a carboxyl group, (xvii) formyl, (xviii) C 1 _ 6 alkyl-carbonyl group, (xix) rubamoyl group, (XX) mono- 6- alkyl rubamoyl group,
- a carboxyl- 6- alkyl group (XXV) a monocyclic or 2- or 4-cyclic heterocyclic group containing 1 to 6 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom (this heterocyclic group, the above substituted a substituent selected from the group R group may also be perforated)
- a ureido group (this ureido groups, - 6 alkyl group, C 6 _ 1 4 Ariru group (this C 6 -, 4 Ariru group consisting of halogen, Ji - 6 Anore kill group, halo _ 6 alkyl group, C x it may also be substituted by _ 6 alkoxy group Rere) or C 7 _, substituted with 6 Ararukiru group
- thioperido group (this thioperide group is — 6 alkyl group, C 6 _ i 4 aryl group (this C 6 —, 4
- amino Chio carboxymethyl el groups - 6 may be an alkyl group optionally mono- or di-substituted
- amino scan Honoré Honi Honoré (the amino scan Honoré Honi Honoré is E -.
- substituent group D This phenoxy may be substituted with halogen (hereinafter, abbreviated as substituent group D).
- the phenoxy may have 1 to 5 substituent (s), linear or branched.
- R 'and R are each a hydrogen atom or a C - 6 alkyl group (this _ 6 ⁇ alkyl group, said substituents D good have 1 to 5 substituents selected from the group Les) a And R 'and R''' are bonded to each other and contain one heteroatom selected from nitrogen, oxygen and sulfur in addition to carbon and two nitrogen atoms. May form a 5- to 9-membered nitrogen-containing heterocyclic ring.
- the agent according to the above (1) which is a group represented by the formula:
- this nitrogen-containing saturated heterocyclic group includes (i) a halogen atom, (ii) a nitro group , (iii) Shiano group, (iv) Okiso group, (V) hydroxy group, (vi) C 1 _ 6 alkyl group (the C - may be substituted with alkyl groups, phenyl), (vii) C 1 -. 6 alkoxy group (this Interview
- Hue - may be substituted with Le), (viii) - 6 ⁇ alkylthio group (this _ 6 alkylthio group, it may also be substituted by phenyl Rere), (ix) amino group , (X) Mono- 6 alkylamino group, (xi) Di-C!
- a carboxyl-C i- 6 alkyl group (XXV) a monocyclic or 2- or 4-cyclic heterocyclic group containing 1 to 6 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom (This heterocyclic group may be replaced by a substituent selected from the above-mentioned substituent group S), (xxvi) a peridot group (the peridot group is — 6 alkyl group, C 6 — 14 Ariru group (this C 6 - 1 4 Arinore groups, halogen, C
- _ 6 alkyl group, halo - may be substituted with 1 6 Ararukiru group), - 6 alkyl group, _ 6 alkoxy it may also be substituted with a group Re,) or C 7
- guanidino group (this guanidino group may be mono- or di-substituted with a 6- alkyl group), (XXX) pyrrolidino carbonyl, piperidinocarbol, (4-methylpyridino) carbonyl, (4-phenylpyridino) force luponil, (4-benzylpiperidino) force luponyl, (4-benzopyridino) force luponil,
- substituent group E A straight-chain or branched 16- alkyl group which may have 1 to 5 groups, a straight-chain or branched C 2 _ 6 alkenyl group, a straight-chain or branched C 2 - 6 alkynyl group, C 3 _ 6 cycloalkyl group, a crosslinked cyclic C 8 -, 4 saturated hydrocarbon groups, C 6 - 4 Ariru group, C 7 _ x 6 Araru kill group, C 6 _, 4 Ariru 1 C 2 ⁇ , 2 alkyl groups, C 6 _, 4 aryl
- phenylthio (this thiol may be substituted with a halogen, which may be substituted with a substituent selected from 6 alkylsulfur groups (hereinafter abbreviated as substituent group T)).
- substituent group T 6 alkylsulfur groups
- phenoxy (this phenoxy may be substituted with a nitrogen atom), and may have 1 to 5 substituents.
- (V) human Dorokishi group (vi) C, _ 6 alkyl group (Konoje - 6 alkyl groups, halogen or Hue - may be substituted with Le), (vii) C 1 _ 6 an alkoxy group (the - 6 alkoxy group, Moyo Rere be substituted by halogen or phenyl), (viii) C x _ 6 alkylthio group (this - 6 alkylthio group, a halogen or Hue - may be substituted by Le ), (Ix) amino group, (X) mono- 6 alkylamino group, (xi) di- 6- alkylamino group,
- xii a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur in addition to carbon and one nitrogen atom, (xiii) C 1 _ 6 alkyl one carbonyl ⁇ amino group, (xiv) _ 6 alkyl Rusuruho - Ruamino group, (XV) - 6 alkoxy - carbonyl group, (xvi) a carboxyl group, (xvii) formyl, (xviii) C x _ 6 alkyl —Calponyl group, (xix) caproluvyl group, (XX) Mono C- 6 alkyl monocanolebamoyl group,
- Nono Russia Ji ⁇ - may be substituted with 1 6 Ararukiru group), - 6 alkyl group, _ 6 alkoxy it may also be substituted with a group Re,) or c 7
- (xxix) guaiacolsulfonate - Jinomoto (This Guanijino group, - 6 may be an alkyl group optionally mono- or di-substituted), (XXX) pyrrolidino force Ruponiru, Piperijinokarubo sulfonyl, (4-methylpiperazin piperidylpiperidine) carbo - le, (4-phenylpyridino) carbol, (4-benzylpyridino) potassium, (4-benzoylpyridino) carbonyl, [4- (4-fluorobenzyl) piperidino] piperidino, Selected from 4-methylbiperazino) carbonyl, (4-phenylbiperazino) carbonyl, [4- (4-nitrophenyl) piperazino] carbonyl, (4-benzylpiperazino) force rpoeel, morpholinocarbonyl, and thiomorpholinocarb
- R ′ and R ′′ are each a hydrogen atom or.
- E _ 6 alkyl group (the Ci - 6 ⁇ alkyl group is, 1 to substituents selected from the substituent group F 5 may have) shows a.
- the agent according to the above (1) which is a group represented by:
- Y is a piperidino group (this piperidino group is
- the ring group includes (i ') a halogen atom, (ii') a nitro group,
- Araruki may be substituted Le group), (xxviii) an amidino group (this amidino group, C one 6 alkyl group or a C 6 _ x 4 Ariru group (this C 6 - 1 4 Ariru group may be mono- or di-substituted with may also) be substituted by nitro group), (xxix) guaiacolsulfonate - Jinomoto (This Guanijino group, - 6 may be an alkyl group optionally mono- or di-substituted), (XXX) pyrrolidino force carbonyl, Pi piperidylpiperidine force Lupo sulfonyl, (4-methylpiperazin piperidylpiperidine) Carbonyl, (4-phenylpiperidino) carbonyl, (4-benzylpiperidino) forced ruponyl, (4-benzoylpiperidino) forced reporter, [4- (4-fluorobenzyl) piperidino]
- substituent group G linear or branched which may have 1 to 5 substituent (s) selected from the group consisting of E - 6 alkyl group, a linear or branched C 2 - 6 alkenyl group, a linear or branched C 2 - 6 alkyl group, C 3 - 6 cycloalkyl group, a crosslinked cyclic C 8 _ x 4 saturated hydrocarbon groups, C 6 - i 4 Ariru group, C 7 _ x 6 Araru kill group, C 6 - Lumpur - C 2 - Luque - le group, C 6 _ i 4 one Roux C
- this heterocyclic group is a substituent group G
- the agent according to the above (1) which may have 1 to 5 substituents selected from, and may be substituted with
- the agent according to (1) which is a preventive or therapeutic agent for hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction or heart failure;
- R 1 represents a hydrogen atom, a hydrocarbon group which may be substituted or an acyl group which may be substituted;
- ring A represents a benzene ring which may further have a substituent;
- Y ′ may be substituted Represents an amino group which may be substituted.
- X is S 0 2 NR 3 a —, -CONR 3 3 — or one CR 3 a (R 3 b ) one (where R 3 a and R 3 b are each independently a hydrogen atom, Shiano group, arsenate Dorokishi group, an amino group, C 1 - compound 6 alkyl or CI- 6 alkoxy group to indicate to) the is a group represented by (20), wherein;.
- R 2 is (1) a hydrogen atom
- R 2 c and R 3 c are each the same or different and each is an ⁇ hydrogen atom, ( ⁇ ) a linear or branched di-- 6 alkyl group, linear or branched c 2 _ 6 alkenyl group, a linear or branched c 2 - 6 Arukini le group, c 3 - 6 cycloalkyl group, a crosslinked cyclic c 8 -, 4 saturated hydrocarbon group , c 6 - 1 4 Ariru group, C 7 _ x 6 Ararukiru group, C 6 _!
- phenoxy (this phenoxy may be substituted by halogen) and may have 1 to 5 substituents selected from the group consisting of: Selected from]
- xii a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom in addition to the carbon atom and one nitrogen atom, Odii) C, _ 6 alkyl one carbonyl ⁇ amino group, (xiv) C 1 _ 6 alkynyl Lou sulfonyl ⁇ amino group, (XV) C x _ 6 alkoxy Ichiriki Lupo two Honoré group, (xvi) a carboxyl group, (xvii) formyl, ( xviii) C 1 _ 6 alkyl one carbonyl group, (xix) force Rubamoiru group, (XX) mono- C 1 - 6 alkyl one Kanorebamoiru group, (xxi) di - 6 alkyl Ichiriki Rubamoiru group, (xxii) C x _ 6 Arukirusu sulfo - le group, (xxii
- Guanijino group (this Guanijino group, - 6 alkyl group may be mono- or di-substituted), (XXX) pyrrolidinocarbonyl, Piperijinokarubo sulfonyl, (4-Mechirubiperijino) carbo - le, (4-Hue Dirubiperidino) carbonyl,
- substituent group H et chosen substituent 1 to 5 have also been or straight-chain or branched - 6 alkyl group, a linear or branched C 2 scratch.
- Alkenyl Group straight or branched C 2 _ g alkynyl, Cg _ 6 cycloalkyl group, a crosslinked cyclic C 8 -, 4 saturated hydrocarbon group, c 6 - i 4 Ariru group, C 7 _, 6 Araru kill group, c 6 _ x 4 Ariru one c 2 one x 2 Aruke - le group, c 6 _ x 4 Ariru one
- R 'and R are each a hydrogen atom or a Ci one alkyl group (this - 6 ⁇ alkyl group, the substituents H it may also have 1 to 5 substituents selected from the group Les) a And R 'and R "may be bonded to each other and contain, in addition to the carbon atom and the two nitrogen atoms, one heteroatom selected from a nitrogen atom, an oxygen atom and a sulfur atom; It may form a nitrogen heterocycle.
- a compound according to the above (16) which is a group represented by the formula:
- R 2 is (1) a hydrogen atom
- R 20 and R 3 c are the same or different and ) a hydrogen atom, (ii) a linear or branched - 6 alkyl group, a linear or branched C 2 - 6 Aruke - group, a linear or branched C 2 _ 6 Anoreki -C 3 — 6 cycloalkyl group, bridged cyclic C 8 ⁇ x 4 saturated hydrocarbon group, C 6 ⁇
- a monocyclic or 2- to 4-cyclic heterocyclic group containing 1 to 6 hetero atoms selected from a nitrogen atom, an oxygen atom or a sulfur atom, or R 2 c and R 3 c May be bonded to each other to form a 5- to 9-membered nitrogen-containing saturated heterocyclic group together with an adjacent nitrogen atom.
- the nitrogen-containing saturated heterocyclic group includes (i) a halogen atom,
- C, _ 6 alkyl group (the ⁇ E - 6 alkyl group may be substituted with Fueeru), (vii) C 1 _ 6 Anorekokishi group (this single 6 Anorekokishi group, Hue - Le may be substituted), (viii) C x _ 6 alkylthio group (the C 1 - 6 alkylthio group, it may also be substituted by phenyl les,), (ix) amino group, (X) mono- - 6 alkylamino groups, (xi) di-. D — 6 alkylamino group,
- xii a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom in addition to the carbon atom and one nitrogen atom, (xiii) C x _ 6 alkyl one Karuboyuruamino group, (xiv) C 1 _ 6 alkynyl Lou sulfonyl ⁇ amino group, (XV) C, _ 6 alkoxy one carbonyl group, (xvi) a carboxyl group, (xvii) C x _ 6 alkyl Ichiriki Lupo two Norre group, (xviii) force Luba moil group, (xix) mono one - 6 alkyl one Kanorebamoiru group, (XX) di ten E one 6 alkyl - Karupamoiru group, (xxi) C 1 _ 6 alkylsulfonyl group,
- alkyl-carbonyl group, (xviii ') is replaced by 6 substituents selected from alkyl sulfonyl group - force Rubamoiru group, (xix) mono- - 6 alkyl force Rubamoiru group, ( ⁇ ') Gee - 6 alkyl force Rubamoiru group and (xxi ') C, Selected from (XXV) phenylthio (this phenylthio may be substituted by halogen) or (xxvi) phenoxy (this phenoxy may be substituted by halogen) And may have 1 to 5 substituents).
- R 2 is (1) a hydrogen atom
- R 2 c and R 3 which are alkyl or (iii) a monocyclic or bi- to tetracyclic heterocyclic group containing 1 to 6 heteroatoms selected from nitrogen, oxygen or sulfur; c may combine with each other to form a 5- to 9-membered nitrogen-containing saturated heterocyclic group together with an adjacent nitrogen atom (this nitrogen-containing saturated heterocyclic group may be (i ') a halogen atom, (ii') - substituted alkyl group is a phenyl - Toromoto, (iii ') Shiano group, (iv) Okiso group, (v) hydroxy group, (vi') C 1 _ 6 alkyl group (the C 1 good), (vii ') C 1 _ 6 alkoxy group (the C _ 6 alkoxy group, Hue - may be substituted with Le), (viii') C x _ 6 alkylthio group (the C 1 _ 6 alkylthio group may be substituted
- R 'and R are each hydrogen or C 1 - 6 an alkyl radical wherein a represented Ru group (1 6) The compound according;
- ⁇ ′ is a piperidino group (this piperidino group is (i) C, 6- alkyl, C C- 6- anoleoxy, halogen atom, nitro, mono- or di-- 6- anolecil-canolebamoyloxy, hydroxy, Shiano, carboxyl, C 1 _ 6 alkoxy Cicarbonyl, carbamoyl, cyclic aminocarbonyl, amino, 6 -alkylcarbonylamino, phenyls / levonylamino, 6- alkylsulfonylamino, amidino, ureido or phenyl optionally substituted by heterocycle
- C 1 _ 6 alkyl (ii) a halogen atom, arsenate Dorokishi, - 6 alkoxy, ⁇ amino, mono - or di. 6- alkylamino, carboxyl, cyano or
- C x _ 6 may be substituted by alkoxy one carbonyl - 6 alkyl group or is (iii) mono- or di - - 6 ⁇ Honoré keno les amino or C 1 - 6 Anorekokishi - may be substituted with a carbonyl d _ 6 alkyl force Lupo - said also good Rere) optionally substituted with Le group (1 6) the compound according;
- Ar represents an aryl group which may be substituted
- X represents a spacer having 1 to 4 atoms constituting the straight-chain portion
- n represents an integer of 1 to 10.
- R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group, which may be the same or different in the repetition of n, and R is bonded to Ar or a substituent of Ar.
- Y represents an amino group which may be substituted or a nitrogen-containing heterocyclic group which may be substituted.
- R 1 1 represents a hydrogen atom or an optionally substituted hydrocarbon group
- X a is the number of atoms constituting the straight chain moiety represents 1 to 1 second spacer
- R 1 1 And X a may combine to form a ring
- a a represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group
- R 12 is a substituted Represents an optionally substituted hydrocarbon group or an optionally substituted amino group
- R 13 represents an optionally substituted hydrocarbon group
- the Ba ring and the Ca ring are each further substituted. Shows a good benzene ring.
- Excluding a method for antagonizing GPR14, which comprises administering an effective amount of a compound represented by the formula or a salt thereof;
- Ar represents an aryl group which may be substituted
- X represents a spacer having 1 to 4 atoms constituting the straight-chain portion
- n represents an integer of 1 to 10
- R is a hydrogen atom or a substituted or unsubstituted hydrocarbon group, which may be the same or different in repeating n
- R is a bond to Ar or a substituent of Ar Y represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group.
- R 1 1 represents a hydrogen atom or an optionally substituted hydrocarbon group
- X a is the number of atoms constituting the straight chain moiety represents 1 to 1 second spacer
- R 1 1 And X a may combine to form a ring
- a a represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group
- R 12 is a substituted Represents an optionally substituted hydrocarbon group or an optionally substituted amino group
- R 13 represents an optionally substituted hydrocarbon group
- the Ba ring and the Ca ring are each further substituted. Shows a good benzene ring. ])
- R 1 has the same meaning as in the above (1), W represents one SO 2 — or one CO—, and Z represents a leaving group. And a salt thereof, and a compound represented by the formula R 3a R
- R 3 a is a hydrogen atom, Shiano group, hydroxy group, an amino group, a C 1 _ 6 Al Kill group or Ji E _ 6 alkoxy group
- R may be a hydrogen atom or a substituent Y 'represents an amino group which may have a substituent
- n' represents an integer of 1 to 10;
- a salt thereof is reacted with a compound represented by the formula
- GPR14 antagonism in the present invention refers to an action of competitively or non-competitively inhibiting the binding of a ligand (such as perotinsin II) to the GPR14 protein on the cell membrane.
- a ligand such as perotinsin II
- drugs that exert various vasoactive actions for example, enhancement or suppression of vasoconstriction
- drugs that are induced by perotinsin II are provided.
- a vasoconstriction inhibitor having an action of attenuating a strong vasoconstriction action is preferably used.
- Such a vasoconstriction inhibitor can be applied as a prophylactic / therapeutic agent for various diseases, but among them, a prophylactic / therapeutic agent for hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction, heart failure, etc. In particular, it is preferably used as a prophylactic / therapeutic agent for ischemic myocardial infarction, congestive heart failure and the like.
- Ar represents “optionally substituted aryl group”.
- Examples of the “substituent” of the “optionally substituted aryl group” include (i) a lower alkyl group which may be halogenated, (ii) a halogen atom (for example, fluoro, chloro, bromo, (Iii) a lower alkylenedioxy group (for example, a C 1-3 alkylenedioxy group such as methylenedioxy and ethylenedioxy), (iv) a nitro group, (V) a cyano group, (vi) a hydroxy group,
- a 5- to 7-membered cyclic amino group which may have one to three heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom in addition to one nitrogen atom (for example, pyrrolidino, piperidino, piperazino, morpholino, etc. Chiomoruhori Bruno), (xiv) lower alkyl one carbonyl ⁇ amino group (e.g., Asechiruami Bruno, propionitrile - Ruamino, etc.
- lower alkylsulfonyl group for example, methyl- 6 -alkylsulfonyl group such as methylsulfonyl, ethyls / lefonyl, propylsulfol, etc.
- lower cycloalkylsulfonyl for example, cyclopentylsulfonyl, such as C 3 _ 6 Shikuroa alkylsulfonyl such as cyclohexyl sulfo El cyclohexane
- Fueeru group for example, a naphthyl group,
- XXX monophenyl lower alkyl group
- xxxi diphenyl lower alkyl group
- diphenyl -C 1- such as diphenylmethyl and diphenylethyl
- Examples of the “optionally lower halogenated lower alkyl group” include, for example, a lower alkyl group optionally having 1 to 3 halogen atoms (for example, chloro, bromo, and odo) (for example, methyl , Ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, etc., alkyl groups, etc., and specific examples are methyl, chloromethyl, difluoro methyl thiol, trichloro Methinole, Trifnoreo mouth Methinole, Ethinole, 21-Promochinole, 2,2,2-Trifluoroethyl, propyl, 3,3,3-Trifluoropropyl, Isopropynole, Butyl, 4,4,4-Trifnoreo Mouth Puchinore, Isobutinore, sec-Puchinore,
- Pentyl, hexyl, and 6,6,6_hexyl trifluoromethyl, etc. are available.
- Examples of the “optionally lower halogenated lower alkoxy group” include, for example, a lower alkoxy group optionally having 1 to 3 halogen atoms (for example, chloro, bromo, and odo).
- lower alkylthio group which may be halogenated include, for example, a lower alkylthio group which may have 1 to 3 halogen atoms (for example, chloro, bromo, and eodo) (for example, methylthio). , 6- alkylthio groups such as ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, tert-butylthio and the like.
- methylthio difluoromethylthio, and trifluoromethyl.
- Oromethylthio, .eti examples thereof include ruthio, n-propynolethio, isopropylthio, n-butylthio, 4,4,4-trifluorofluorothio, isobutynolethio, sec-butynolethio, tert-butynolethio, pentylthio, and hexylthio.
- di-lower alkylamino group for example, di-Ci- 6- alkylamino group such as dimethylamino, getylamino, etc.
- nitrogen atom, oxygen atom and sulfur atom other than one nitrogen atom A 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms (for example, pyrrolidino, piberidino, piperazino, morpholino, thiomorpholino, etc.),
- V) a lower alkyl monovalent ruponylamino group for example, acetylamino) , Propionylamino, butyrylamino, etc., Ci- 6 alkyl-carbonylamino group, etc.
- aminocarbonyloxy group for example, methyl / reaminocano
- xii phenylalanine sulfonyl ⁇ amino group
- a halogen atom e.g., Furuo port, chloro, etc.
- xiv lower optionally halogenated (e.g., E -. 6) alkyl group (e.g., methyl , Ethyl, isopropynole, tert-butyl, triflu Oromechinore etc.) and
- XV may lower an optionally halogenated (e.g., E -.
- Anorekokishi group e.g., methoxy, ethoxy, isopropoxy, tert - butoxy, triflumizole Ruo b methoxy, etc.
- a 5- to 7-membered cyclic amino group which may have, in addition to one nitrogen atom, one to three heteroatoms selected from a nitrogen atom, an oxygen atom and a sulfur atom (for example, pyrrolidino, piperidino, piperazino, Morpholino, thiomorpholino, etc.).
- the " ⁇ aryl group" of the "optionally substituted Ariru group” represented by A r for example, phenyl, C 6, such as naphthyl - 1 4 Ariru, preferably C 6 one x.
- Aryl more preferably phenyl and the like.
- the “aryl group which may be substituted” may be such that the substituents in the “aryl group” may be bonded to each other to form a condensed ring, and the aryl group as Ar (preferably a phenyl group) Examples of a group in which a condensed ring forms
- aryl group in the “optionally substituted aryl group” is condensed with a monocyclic heterocyclic ring which may have a substituent include, for example,
- ring B represents a heterocyclic ring which may have a substituent
- ring A represents a benzene ring which may have a substituent
- substituent on ring A examples include the same substituents as those described above for the “optionally substituted aryl group”.
- substituent (s) represented by ring B
- a 4- to 14-membered ring preferably a 5- to 9-membered ring and the like are used. It can be either non-aromatic.
- hetero atom for example, 1 to 3 or 4 selected from a nitrogen atom, an oxygen atom, a sulfur atom and the like are used.
- 5- to 9-membered non-aromatic heterocycles containing one heteroatom or two identical or different heteroatoms are used.
- 5- to 9-membered non-aromatic heterocycles containing one heteroatom or two identical or different heteroatoms eg, pyrrolidine, piperidine, hexamethyleneimine, heptaimine
- Methyleneimine e.g, tetrahydrofuran, piperazine, homopidazine, tetrahydrooxazepine, morpholine, thiomorpholine and the like are preferred.
- Non-aromatic heterocycles containing heteroatoms are frequently used.
- the “substituent” of the “optionally substituted heterocycle” represented by ring B may be substituted on any carbon atom of ring B.
- Examples of the substituent on any carbon atom of the ring B include (i) a halogen atom (eg, fluoro, chloro, bromo, and odo), (ii) a nitro group, (iii) a cyano group, and (iv) Oxo group, (v) hydroxy group, (vi) lower alkyl group (for example, methyl, ethyl, propyl, isopropyl, butyl, isoptyl, tert-butyl, sec-butyl, etc.)- 6 alkyl group, etc.
- a halogen atom eg, fluoro, chloro, bromo, and odo
- a halogen atom eg, fluoro, chloro, bromo, and odo
- a nitro group e.g., a nitro group
- iii) a cyano group e.g., a cyano group
- lower alkoxy group e.g., main butoxy, ethoxy, n- Puropiruo alkoxy, i one Puropinoreokishi, etc.
- Flip E _ 6 alkoxy group such as n- Buchiruokishi
- a lower alkylthio group e.g., methylthio, Echiruchio, propylidene ( 6 ) alkylthio group such as luthio
- (ix) amino group (X) mono-low Grade alkylamino group (e.g., Mechiruamino, Echiruamino, which mono- C for Puropiruamino - such as 6 Arukiruamino group), (xi) di-one lower Arukiruamino group (e.g., Jimechiruamino, di one such Jechiruamino - such as 6 ⁇ Kiruami cyano group.)
- ⁇ - 6 alkyl-carbonylamino groups such as acetylamino, propionylamino, butyrylamino, etc.
- lower alkylsulfonylamino groups for example, methylsulfonylamino, ethylsulfonylamino, etc.
- mono-lower alkyl rubamoyl group for example, monocarbamoyl, ethylcarbamoyl, etc .; 6- alkyl rubamoyl group
- an oxo group and a lower alkyl group are preferred, and oxo groups are generally used. Is done.
- a methyl- 6- alkyl group such as methyl, ethyl, propyl, isopropylinole, petitinole, isoptinole, tert-butynole, sec-butinole, etc.
- ring B when ring B has a nitrogen atom in the ring, it may have a substituent on the nitrogen atom. That is, the ring B is
- R 1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted acyl group or an optionally substituted heterocyclic group.
- the “hydrocarbon group” of the “optionally substituted hydrocarbon group” represented by R 1 represents a group obtained by removing one hydrogen atom from a hydrocarbon compound, and examples thereof include an alkyl group, Examples thereof include a chain or cyclic hydrocarbon group such as an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group, and an aralkyl group. Among them, a C i -x 6 hydrocarbon group composed of a chain, a ring, or a combination thereof is preferably used. As a chain or cyclic hydrocarbon group,
- linear or branched lower alkyl group e.g., methyl, Echiru, pro Pinore, isopropylidene Honoré, Buchinore, Isobuchinore, tert - Puchinore, sec- Puchinore, pentyl to, such as cyclohexyl E -. 6 Alkyl group
- linear or branched lower alkyl group e.g., methyl, Echiru, pro Pinore, isopropylidene Honoré, Buchinore, Isobuchinore, tert - Puchinore, sec- Puchinore, pentyl to, such as cyclohexyl E -. 6 Alkyl group
- linear or branched lower alkynyl group e.g., propargyl, E Ji alkenyl, Buchuru, the 1-C 2, such hexynyl - such as 6 alkynyl group
- a monocyclic lower cycloalkyl group e.g., cyclopropyl, Shikuropuchiru, cyclopentyl, monocyclic C 3 _ 6 cycloalkyl group such as cyclohexyl
- Bridged cyclic lower saturated hydrocarbon groups for example, bicyclo [3.2.1] ototo-2-yl, bicyclo [3.3.1] non-1--2-yl, adamantane-1-yl, etc. crosslinked cyclic C 8 one 1 4 saturated hydrocarbon group), or
- aryl groups for example, C 6 ⁇ 4 aryl groups such as fuel, 1-naphthyl, 2-naphthyl, biphenyl, 2-indenyl, 2-anthryl, etc., preferably ferul groups;
- hydrocarbon group consisting of a combination of a chain and a ring,
- Lower aralkyl groups for example, ferul- 1 .
- Alkyl for example, Nginole, fuenoretchinore, feninolepropynole, feninolebutynole, feninolepentyl, feninolehexyl, etc.
- naphthyl- 6- alkyl eg, ⁇ -naphthylmethyl, etc.
- diphenyl-1--3-alkyl for example Jifue two Rumechi Le, C 7 such Jifueniruechiru etc.
- Ararukiru group such as,
- Ariruaruke - Le group e.g., styryl, cinnamyl, 4 one Hue - Le one 2-Buteninore, such as 4-Fueenore one 3- Buteninore phenylene Honoré _ C 2 _ 1 2 Anore Kenyir such C 6 - 4 Aryl C 2 _ 1 2 alkaryl group, etc.
- Ariruaruke - Le group e.g., styryl, cinnamyl, 4 one Hue - Le one 2-Buteninore, such as 4-Fueenore one 3- Buteninore phenylene Honoré _ C 2 _ 1 2 Anore Kenyir such C 6 - 4 Aryl C 2 _ 1 2 alkaryl group, etc.
- Ariru _ C 2 - 1 2 alkyl - Le group e.g., Fueniruechuru, 3 full Eninore one 2 one Puropininore, 3-phenylene Honoré one 1-phenylene, such as single Puropininore Honoré one C 2 _ 1 2 alkyl - C 6 ⁇ , 4 aryl-C 2 ⁇ x 2 alkynyl groups, etc.
- Ariru _ C 2 - 1 2 alkyl - Le group e.g., Fueniruechuru, 3 full Eninore one 2 one Puropininore, 3-phenylene Honoré one 1-phenylene, such as single Puropininore Honoré one C 2 _ 1 2 alkyl - C 6 ⁇ , 4 aryl-C 2 ⁇ x 2 alkynyl groups, etc.
- Lower cycloalkyl-lower alkyl group (for example, cyclopropylmethyl,, cyclobutynolemethinole, pentopen / remethyle, cyclohexizolemethinole, cycloheptylmethinole, cyclopropylethyl, cyclobutylethyl, cyclopentyl) Etinolle, cycinol hexinolechinole, sikh heptinolethyl, cyc propylpropinole, cyc butylinolepropyl, cyc pentylpropyl, cyc hexylpropyl, cyc heptinolpropyl, cyc propyl / levbutinole, Cyclopentyl butyl, cyclopentyl butyl, cyclohexyl butyl, cycloheptyl
- Alkyl groups for example, biphenyl such as biphenylmethyl, biphenylethyl, etc. __________. 1. Alkyl are preferably used.
- a linear, branched or cyclic alkyl group preferably a straight-chain or branched - 6 alkyl group (e.g., methyl, Echiru, propyl, isopropyl, Puchinore, Isopuchinore, tert- Puchinore, sec - C such as petit nore, pentinole, hexinole !
- cyclic C 3 one 8 alkyl group e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexylene hexyl, etc.
- a linear, branched Ah Rui consists of a combination of the annular c 4 - 1 2 alkyl groups (eg, cyclopropinolemethinole, cyclopentinolemethinole, cyclohexinolemethinole, cyclohexinoleethyl, (4-methylcyclohexyl) methyl, etc.) or
- C 7 _, 6 aralkyl group eg, fenir ⁇ ⁇ -1 .
- Alkyl eg, benzinole, feninoletinole, fenolepropinele, feninolebutinole, feninolepentyl, phenhexyl, etc.
- Naphthyl- 6 alkyl eg, ⁇ -naphthylmethyl, etc.
- diphenyl-3-alkyl eg, diphenylmethyl, diphenylethyl, etc.
- phenolene such as benzinole, feninolechichinore, feninolepropinole
- the “hydrocarbon group” represented by R 1 may have a substituent, and as such a substituent, those generally used as a substituent of a hydrocarbon group can be used as appropriate. Specifically, (i) a halogen atom (for example, fluoro, chloro, bromo, eodo, etc.), (ii) a nitro group, (iii) a cyano group, (iv) an oxo group,
- di-one-lower alkylamino group e.g., Jimechiruamino, G. C, such Jechiruamino - such as 6 alkylamino amino group
- a carbon atom and a nitrogen atom in addition to one nitrogen atom, oxygen original 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from sulfur atom and the like (eg, pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, etc.), dii) Alkyl-carboelamino group (for example, C- 6 alkyl-carbonylamino group such as acetylamino, propionylamino, butyrylamino, etc.), (xiv) lower alkylsulfonylamino group (for example, methylsulfonylamino, ethyl) Such as sulfonyla
- Rubamoiru group (Cai Cai) di - lower alkyl - power Rubamoiru group (eg example, dimethylcarbamoyl, such as GETS Chi carbamoyl - such as 6 alkyl Lou force Rubamoiru group), God) lower alkylsulfonyl group (e.g., methylcarbamoyl Bruno Lesnole Honinore, Etilsulfo Le, C, such as pro Pinot less Honoré Honi Honoré, -. Etc.
- dimethylcarbamoyl such as GETS Chi carbamoyl - such as 6 alkyl Lou force Rubamoiru group
- God lower alkylsulfonyl group
- methylcarbamoyl Bruno Lesnole Honinore, Etilsulfo Le, C, such as pro Pinot less Honoré Honi Honoré, -. Etc.
- Anorekiru sulfonyl group (xx ii) lower alkoxy one carbo - Lou lower alkyl group (e.g., main Toki Shikano repo Nino les methylate Honoré, ethoxy Kano repo Nino les methyl, tert-butoxycarboelmethyl, methoxycarbonylethyl, methoxycarbonylmethyl, methoxycanoleponyl (dimethyl) methyl, ethoxycarbonyl (dimethyl) methyl, tert-butoxycarbol (dimethyl) methyl, etc.
- main Toki Shikano repo Nino les methylate Honoré ethoxy Kano repo Nino les methyl
- tert-butoxycarboelmethyl methoxycarbonylethyl
- methoxycarbonylmethyl methoxycarbonylmethyl
- methoxycanoleponyl (dimethyl) methyl, ethoxycarbonyl (dimethyl)
- E _ 6 alkoxy one carbonylation Lou d - 6 such as an alkyl group
- carboxy - lower alkyl group e.g., carboxyl methyl, carboxyl E chill force Rupokishiru (dimethyl chill) carboxyl over C one s alkyl such as methyl And
- a group which may have a substituent e.g., Ring group, (XXV) alkyl group which may have a substituent,
- the “substituent” of the “optionally substituted hydrocarbon group” represented by R 1 preferably a halogen atom, an alkyl group optionally having a substituent, or a substituent also alkoxy group, a hydroxyl group, a nitro group, Shiano group, carboxyl group, C, - 6 alkoxycarbonyl - group, forces Rubamoiru group, amino Chio carbo - group, mono- lower alkyl Ichiriki Rubamoiru group, di-lower alkyl one Nitrogen, oxygen atom other than carbon atom and one nitrogen atom, and a carbamoyl group, an optionally substituted cyclic aminocarbonyl group, an amino group, a mono-lower alkylamino group, a di-lower alkylamino group And a 5- to 7-membered cyclic amino group which may have 1 to 3 heteroatoms selected from a sulfur atom and the like, a C i _ 6 alkylamino group
- the “heterocyclic group” of the “heterocyclic group optionally having substituent (s)” includes a monocyclic bicyclic ring, a bicyclic heterocyclic ring, and a tricyclic or tetracyclic polycyclic ring. A group formed by removing one hydrogen atom from the formula heterocycle is used.
- the heterocyclic ring may be either aromatic or non-aromatic. As the hetero atom, for example, 1 to 6 atoms selected from a nitrogen atom, an oxygen atom, a sulfur atom and the like are used.
- the monocyclic heterocyclic group a group formed by removing one hydrogen atom from the “heterocycle” of the “heterocycle optionally having substituent (s)” represented by the ring B is used.
- groups formed by removing one hydrogen atom from a monocyclic heterocycle such as triazole, thiadiazole, oxaziazole, oxthiadiazole, triazine, and tetrazole are also used.
- bicyclic heterocyclic group examples include, for example, indole, dihydroindole, isoindole, dihydroisoindole, benzofuran, dihydrobenzofuran, benzimidazole Nore, Indazonole, Quinoline, Tetrahydroquinoline, Isoquinoline, Tetrahydroisoquinoline, Tetrahydr Mouth-1H-1_Benzazepine, Tetrahydro-1H-2-benzazepine, Tetrahydro-
- polycyclic heterocyclic group such as tricyclic or tetracyclic
- examples of the polycyclic heterocyclic group include those derived from polycyclic heterocyclic rings such as ataridine, tetrahydroacridine, pyroquinoline, pyroindoinole, cyclopentoindonole, and isoindrobenzazepine.
- a group formed by removing one hydrogen atom is used.
- heterocyclic group of the “heterocyclic group optionally having substituent (s)
- substituent (s) particularly a group formed by removing one hydrogen atom from the above-mentioned monocyclic heterocyclic ring or bicyclic heterocyclic ring
- Alkyl optionally having a substituent (preferably optionally having a substituent
- C, _ 6 alkyl) "or” optionally substituted alkoxy (rather preferably may have a substituent - "substituent” of 6 Anorekokishi) ", for example, the R (I) to (xxiv) or (xxvii) to (xxxxii) as a "substituent” of the "optionally substituted hydrocarbon group” represented by 1 "Substituent” and the like are used.
- Optionally substituted ureido group "optionally substituted thioureido group”, “optionally substituted amidino group”, “optionally substituted Guanidino group “,” cyclic aminocarbonyl group optionally having substituent (s) ",” aminothiocarbonyl group optionally having substituent (s) “” amino optionally having substituent (s) "
- Examples of the “sulfonyl” or the “optionally substituted phenylsulfoninoleamino j ⁇ ⁇ substituent” include the “optionally substituted hydrocarbon group” represented by R 1 above.
- substituent group "(i) ⁇ (XX vi) Moshiku are shown in (xxxv) ⁇ (xxxxii)" substituent ", C 6 - i 4 Ariru group (the C 6 - 1 4 Ariru group, halogen, - 6 alkyl group, Nono b - 6 alkyl group, C, - 6 alkoxycarbonyl Sheet group and - like Toro etc. but it may also have a substituent group selected from the group) or C 7 _ 1 6 Ararukiru group is used.
- Lou C t _ 6 alkyl group with substituents such as alkoxy may be mentioned More preferably, they are 1-4 alkyl (such as methyl) and trinoperogeno. ⁇ _, alkyl (such as methyl), halogen atom (Furuoro, black hole, etc.), nitro, Shiano, - 4 alkoxy (methoxy, etc.), Application Benefits Bruno, Rogeno one 4 alkoxy (such as main butoxy), hydroxy, force Rubamoi ⁇ ⁇ (4 - such as C 1 _ 4 alkyl (methyl) -1 - piperazinyl) carboxamide - le, Aminochiokaru port - le, Moruhorinokarubo - Le, carboxyl, C 1 _ 4 alkoxy (such as main butoxy)
- R 1 is. 4- alkyl (such as methyl), trihalogeno (such as fluoro) — 4- alkyl (such as methyl), halogen atom (such as fluoro and chloro), nitro, cyano, rubamoyl, and 4- alkoxy (such as methoxy) . — 4 alkoxy (such as ethoxy) carbonyl 0 1 ⁇ 4 alkoxy
- R SO.
- R 2c and R 3c are They may combine to have a substituent together with an adjacent nitrogen atom, and may form a nitrogen-containing saturated heterocyclic group. ].
- R 2c and R 3c represented by an “optionally substituted hydrocarbon group”
- Hydrocarbon group refers to a group in which one hydrogen atom has been removed from a hydrocarbon compound, and examples thereof include an alkyl group, an alkenyl group, an alkyl group, a cycloalkyl group, an aryl group and an aralkyl group. And a chain or cyclic hydrocarbon group. Specific examples include the same groups as the “hydrocarbon group” of the “optionally substituted hydrocarbon group” for R 1 above, and among them, a chain or cyclic group.
- X 6 hydrocarbon groups and the like are preferable, and particularly, lower (J— 6 ) alkyl groups and lower (C 2 — 6 ) Kenyir group, C 7 _ 1 6 Ararukiru group or C 6 - x 4 Ariru group. Kana even lower (C x _ 6) alkyl group, C 7 _, 6 Ararukiru group or c 6 one 1 4 Ariru group is generic.
- R 2 c and R 3 represented by c 'Yo be substituted les, heterocyclic group "as the" double ring group ", a monocyclic heterocycle, bicyclic heterocycle and, A group obtained by removing one hydrogen atom from a polycyclic heterocyclic ring such as tricyclic or tetracyclic is used.
- the heterocyclic ring may be either aromatic or non-aromatic.
- the hetero atom for example, 1 to 6 atoms selected from a nitrogen atom, an oxygen atom, a sulfur atom and the like are used.
- the monocyclic heterocyclic group can be formed by removing one hydrogen atom from the “heterocycle” of the “heterocycle optionally having a substituent” represented by ring B above. Groups are used. Further, in addition thereto, for example, a group formed by removing one hydrogen atom from a monocyclic heterocycle such as triazole, thiaziazole, oxaziazol / l, oxthiadiazol, triazine, and tetrazole is also used.
- bicyclic heterocyclic group examples include, for example, indole, dihydroindole, isoindole, dihydroisoindole, benzofuran, dihydrobenzozofuran, benzimidazolone, benzisoxazole, benzisoisoxazonone, benzothiazole, indazole, quinoline, tetrahydro Quinoline, isoquinoline, tetrahydroisoquinoline, tetrahydro-1H-tobenzazepine, tetrahydro-1H-2-benzazepine, tetrahydro-1H-3-benzazepine, tetrahydrobenzoxazepine, quinazoline, tetrahydroquinazoline, quinoxinaline Removal of one hydrogen atom from bicyclic heterocycles such as oxonole, benzothiazine, imidazopyridine, etc.
- polycyclic heterocyclic groups such as tricyclic or tetracyclic
- polycyclic groups such as ataridine, tetrahydroacridine, quinoline having a lipo, indone ole having a lipo, cyclopentindole, and isoindrobenzazepine.
- a group formed by removing one hydrogen atom from a heterocycle is used.
- heterocyclic group of the “heterocyclic group optionally having substituent (s)"
- R 2 e and R 3 c may be formed together with an adjacent nitrogen atom.
- the “optionally substituted nitrogen-containing saturated heterocyclic group” includes, in addition to a carbon atom and one nitrogen atom, A 5- to 9-membered nitrogen-containing saturated heterocyclic group which may have 1 to 3 hetero atoms such as a nitrogen atom, an oxygen atom and a sulfur atom is used.
- nitrogen-containing saturated heterocyclic groups groups having a bond at the ring-constituting nitrogen atom are preferred. Examples of the group having a bond at the ring-forming nitrogen atom include, for example, a group represented by the formula
- Preferred substituents that may be possessed by the ⁇ hydrocarbon group '' or ⁇ heterocyclic group '' represented by R 2 c and R 3 c , and the ⁇ nitrogen-containing saturated heterocyclic group '' represented by NR 3 c R 2c Is, for example, (i) a halogen atom (for example, fluoro, chloro, bromo, odo, etc.), (ii) nitro, (iii) cyano, (iv) oxo, (v) hydroxy, (vi) substitution A hydrocarbon group which may have a group, (vii) a lower alkoxy group which may be substituted by a phenyl group (for example, methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy and the like) ⁇ 6 alkoxy groups ), (Viii) a lower alkylthio group optionally substituted with a phenyl group (for
- (ix) amino group amino group, (X) mono one lower alkylamino group (e.g., Mechiruamino, Echiruamino, such as mono one C one 6 Arukiruamino group such Puropiruamino), (xi) di-lower alkylamino group (e.g., Jimechiruamino, Jechiruamino etc.
- mono one lower alkylamino group e.g., Mechiruamino, Echiruamino, such as mono one C one 6 Arukiruamino group such Puropiruamino
- di-lower alkylamino group e.g., Jimechiruamino, Jechiruamino etc.
- di C - such as 6 Arukiruamino group
- a 5- to 7-membered cyclic amino group eg, pyrrolidino, piperidino, piperazino, morpholino, thiomorpholino, etc.
- C i- 6 alkyl-carbonylamino group
- a lower alkyl monosulfo-amino group for example, a Ci- 6 alkyl-sulfonylamino group such as methylsulfonylamino, ethylsulfonylamino and the like
- XV a lower alkoxy-monocarbonyl group (for example, butoxycarbonyl, ethoxycarbonyl, propoxycarbonyl carbo - Le etc. - 6 etc. alkoxy one carbonyl group)
- a carboxyl group for example, butoxycarbonyl, ethoxycarbonyl, propoxycarbonyl carbo - Le etc. - 6 etc. alkoxy one carbonyl group
- a carboxyl group for example, butoxycarbonyl, ethoxycarbonyl, propoxycarbonyl carbo - Le etc. - 6 etc. alkoxy one carbonyl group
- xvi a carboxyl group
- xvii lower alkyl - group (e.
- lower alkoxy group and “lower alkylthio group” may further have a phenyl group as a substituent.
- substituted hydrocarbon group of the “optionally substituted hydrocarbon group” include the “optionally substituted hydrocarbon group” represented by R 1 above.
- the “heterocyclic group” of the “heterocyclic group optionally having substituent (s)” represented by ring B above A group formed by removing one hydrogen atom is used.
- R 2 c and R 3 c preferably, 4- phenyl (methyl, ethyl, etc.) or 4- alkoxy (methoxy, ethoxy, etc.) which may be substituted with pheninole, 4- aminolequinole (methinole, etinole, etc.), norogeno (fluoro, black, etc.) C alkyl (Methyl, ethyl, etc.), benzyl, naphthyl, pyridyl, chenyl, furyl or hydrogen atom.
- acetyl group represented by R 1 , preferably, formyl, acetyl, torino, logeno (e.g., fluoro) acetyl, pyridylcarbonyl, chenylcarbonyl, furylcarbonyl, phenacyl, benzoyl, C x - 4 alkyl (such as methyl) Benzoiru, C - 4 alkoxy (methoxy, etc.) Benzoinore, benzene scan Honoré Honi Honoré, naphthoquinone Chino less Honoré Honi Honoré, etc.
- logeno e.g., fluoro
- acetyl pyridylcarbonyl
- chenylcarbonyl chenylcarbonyl
- furylcarbonyl chenylcarbonyl
- phenacyl phenacyl
- benzoyl C x - 4 alkyl (such as methyl) Benzoiru, C
- a ( C 0) - [wherein, R 2 c is - 6 alkyl group, C x _ 6 alkoxy group optionally substituted phenyl group or an off E - Lou d - shows the 6 alkyl group] R 2 c, etc. Is raised.
- Examples of the “heterocyclic group” of the “optionally substituted heterocyclic group” represented by R 1 include a monocyclic heterocyclic ring, a bicyclic heterocyclic ring, and a tricyclic or tetracyclic polycyclic ring. A group formed by removing one hydrogen atom from the formula heterocycle is used.
- the heterocycle may be aromatic or non-aromatic.
- the hetero atom for example, 1 to 6 atoms selected from a nitrogen atom, an oxygen atom, a sulfur atom and the like are used.
- the monocyclic heterocyclic group can be formed by removing one hydrogen atom from the ⁇ heterocyclic '' force of the ⁇ optionally substituted heterocyclic ring '' represented by ring B above. Groups are used.
- a group formed by removing one hydrogen atom from a monocyclic heterocycle such as triazole, thiadiazole, oxazidazole, oxthiadiazole, triazine, and tetrazole is also used.
- bicyclic heterocyclic group examples include indole, dihydroindole, isoindole, dihydroisoindoleno, benzofuran, dihydrobenzofuran, benzimidazonole, benzoxazonole, benzisoxazole, benzothiazonole, Indazonole, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, tetrahydro-1H-1-benzazepine, tetrahydro-1H-2-benzazepine, tetrahydro-1H-3-benzazepine, tetrahydrobenzoxazepine, quinazoline, tetrahydroquinoxaline, tetrahydroquinoxaline , Benzodioxane, benzodioxole, benzothiazine, imidazopyridine and other bicyclic heterocycles by
- Such as a group are used.
- the polycyclic heterocyclic group such as tricyclic or tetracyclic include a hydrogen atom from a polycyclic heterocyclic ring such as ataridine, tetrahydroacridine, pyroquinoline, pyroindone, cyclopentoindole, and isoindolobenzazepine.
- a group formed by removing one is used.
- heterocyclic group of the “heterocyclic group optionally having substituent (s)"
- substituent (s) particularly a group formed by removing one hydrogen atom from the above-mentioned monocyclic heterocyclic ring or bicyclic heterocyclic ring And the like are frequently used, and among them, a pyridyl group is preferable.
- aryl group of the “optionally substituted aryl group” is condensed with a monocyclic heterocyclic ring which may have a substituent include:
- Benzothiazepines such as 1-benzothiazepine; 2,3,4,5-tetrahydro-1H-1,2-benzodiazepine, 2,3,4,5-tetrahydro-1H-1,3-benzodiazepine, 2,3 , 4,5-tetrahydro-1H-1,4-benzodiazepine, 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine, 2,3,4,5-tetrahydro-1H- 2, 3 _ benzodiazepine, 2, 3, 4,
- Benzodiazepines such as 5-tetrahydro-1H-2,4-benzodiazepine; 4,5-dihydro-1,3-benzodioxepin; 4,5-dihydro-3H-1,2-benzodiazepine; 2,3 —Dihydro-5H—1,4_benzodioxepin, 3,4 dihydro-1H—1,5-benzodioxepin, 4,5-dihydro_1H—2,3-benzodioxepin, 1 Benzodioxepins such as, 5-dihydro-1,2,4-benzodioxepin; 4,5-dihydro-1H-2,3-benzozopine; 1,5-dihydro-1,2,4-benzodichepine; Benzodicepine, such as —dihydro-2H—1,5-benzodichepine, 2,3-dihydro-5H-1,4-benzodichepine; 3,4,5,6-t
- aryl group of the “optionally substituted aryl group” is condensed with a monocyclic heterocyclic ring which may have a substituent include, for example,
- ring B and ring 5 represent a 5- to 9-membered nitrogen-containing heterocyclic ring which may be substituted with an oxo group other than R 1 , and ring A and R 1 are as defined above. ] And the like.
- a 5- to 9-membered nitrogen-containing heterocyclic group which may contain 1 to 3 hetero atoms such as a nitrogen atom, an oxygen atom and a sulfur atom, and a 5 to 9-membered non-aromatic Nitrogen-containing heterocycles (eg, pyrrolidine, piperidine, hexamethyleneimi , Heptamethyleneimine, piperazine, homopirazine, tetrahydroxazepine, morpholine, thiomorpholine, etc.) are preferably used. More preferred examples of the case where the ⁇ aryl group '' of the ⁇ optionally substituted aryl group '' is condensed with a monocyclic heterocyclic ring which may have a substituent include
- a ring and R 1 have the same meanings as above, and k and m each independently represent an integer of 0 to 5, and 1 is k + m + 5. ]
- k and m each independently represent an integer of 0 to 5, and 1 is k + m + 5.
- R 1 is as defined above.
- Particular preferable examples are:
- R 1 is as defined above.
- ⁇ aryl group '' of the ⁇ aryl group optionally substituted '' represented by Ar is fused with a bicyclic heterocyclic ring which may have a substituent, or two identical or two Specific examples of the case of condensing with a different monocyclic ring (where at least one ring is a monocyclic heterocyclic ring) include, for example,
- ring A has the same meaning as described above, and ring C and ring D are heterocyclic rings, one of which may have a substituent, and the other of which may have a substituent.
- heterocycle of the “heterocycle optionally having substituent (s)" represented by ring C and ring D, for example, a 4- to 14-membered heterocycle, preferably a 5- to 9-membered heterocycle, etc.
- the heteroatom is, for example, one to three selected from a nitrogen atom, an oxygen atom and a sulfur atom. Further, it may be aromatic or non-aromatic.
- pyridine, pyrazine, pyrimidine, imidazole, franc, thiophene, dihydropyridine, diazepine, oxazepine, pyrrolidine, piperidine, hexamethyleneimine, heptamethyleneimine, tetrahydrofuran, piperazine, homopyridine Perazine, tetrahydrooxazepine, monorephorin, thiomorpholine, etc. are used.
- the ring include a 5- to 9-membered heterocyclic ring (for example, pyridine, pyrazine, pyrimidine, imidazo ⁇ ⁇ , furan, thiophene, dihydropyridine, diazepine, oxazepine, pyrrolidine, pyridine, hexamethyleneimine, heptamethyleneimine) ,
- a saturated or unsaturated 5- to 9-membered heterocyclic ring such as tetrahydrofuran, piperazine, homopidazine, tetrahydrooxazepine, morpholine, thiomorpholine, etc.
- a 5- to 9-membered carbocyclic ring is used.
- the “5- to 9-membered carbocycle” may be a saturated or unsaturated ring, for example, benzene, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptene, Cyclohebutadiene and the like are used. Above all, benzene, cyclized hexane and the like are preferable.
- the ⁇ substituent '' of the ⁇ 5 to 9-membered ring which may have a substituent and which may contain a heteroatom atom '', the ⁇ optionally having a substituent It has the same meaning as ": a substituent on any carbon atom of ring B" in "good heterocycle".
- aryl group of the “optionally substituted aryl group” represented by Ar condenses with the bicyclic heterocyclic ring which may have a substituent
- a phenyl group fused to a bicyclic heterocyclic ring represented by, for example, 1H, 3H-naphtho [1,8-cd] [1,2] oxazine, naphtho [1,8-de] -1, 3-oxazine, naphtho [1,8-de] 1-1,2-oxazine, 1,2,2a, 3,4,5-hexahydrobenz [ cd ] indole, 2,3,3a , 4,5,6-Hexahydro-1H-benzo [de] quinoline, 4H-pyro mouth [3,2,1-ij] quinoline, 1,2,5,6-tetrahydro-4H-pyro mouth [3, 2, l-ij] quinoline, 5,6-dihydro-14H-pyrro [3,2,1-ij] quinoline, 1H, 5H-benzo [: Lj] quinolidine, azepino [3,2,1 — Hi] Indole
- a phenyl group fused to two identical or different rings represented by the formula (where at least one ring is a monocyclic complex ring) for example, 1, 2, 3, 6, 7, 8- Removal of one hydrogen atom from a tricyclic fused benzene ring such as oxahydrocyclopent [e] indone, 2,3,4,7,8,9-hexahydro-1H-cyclopenta [f] quinoline And groups that can be used.
- Preferred examples of the case where the ⁇ aryl group '' of the ⁇ optionally substituted aryl group '' represented by Ar is condensed with a bicyclic heterocyclic ring which may have a substituent include, for example, formula
- a 5- to 9-membered nitrogen-containing heterocyclic group which may contain 1 to 3 hetero atoms such as a nitrogen atom, an oxygen atom and a sulfur atom, and a 5 to 9-membered non-aromatic nitrogen-containing group;
- Heterocycles eg, pyrrolidine, piperidine, hexamethyleneimine, heptamethyleneimine, piperazine, homopirazine, tetrahydroxazepine, morpholine, thiomorpholine, etc.
- oxo group for example, other than a carbon atom and one nitrogen atom
- Heterocycles eg, pyrrolidine, piperidine, hexamethyleneimine, heptamethyleneimine, piperazine, homopirazine, tetrahydroxazepine, morpholine, thiomorpholine, etc.
- ring A has the same meaning as described above, and at least one of ring E, ring F and ring G is a heterocyclic ring which may have a substituent, and other rings are It represents a 5- to 9-membered ring which may have a substituent and may contain a hetero atom. ] And the like.
- E-ring, F-ring and G-ring which may have a substituent and may contain a hetero atom, and may contain a hetero atom.
- the ⁇ or 9-membered ring '' and the ⁇ substituent '' the ⁇ 5- to 9-membered ring which may have a substituent and may contain a hetero atom '' represented by the above-mentioned C ring and D ring
- a "5- to 9-membered ring which may contain a hetero atom" and a "substituent" are used.
- a good example is the expression (1) A phenyl group fused with a tricyclic heterocyclic ring represented by the formula [ For example, 2H-isoindolo [2,11 e] purine, 1H-pyrazo mouth [4,3,3: 3,4] pyrido [2,11a] isoindole, 1H-pyrido 2 ,, 3,: 4,5] imidazo [2,11a] isoindole, 2H, 6H-pyrido [1 ,,
- indolo [1,2-b] isoquinoline, indolo [2,1-a] isoquinoline, indolo [1,2_a] quinoline, 2H, 6H 2 ', 1': 3, 4] [1, 4] diazepino [l, 2-a] indole, 1H-indolo [2, 1-c] [1, 4] benzodiazepine, 2H-indolo [1, 2 1 d] [1, 4] Benzodazepine, 2H-indolo [2, 1-a] [2, 3] Benzodazepine, 2H-indolo [2, l-b] [1, 3] Benzodazepine, 1H — Indolo [1 , 2-b] [2] benzazepine, 2H-indolo [1, 2-a]
- 1,2-hij] quinoline 7, 1 1-methanoazosino [1,2-a] indole, 7,11-methanoazosino [2,1-a] isoindole, dibenz [cd, f] indone nore, dibenz [Cd, g] Indonele, dibenz [d, f] Indonele, 1H-dibenz [e, g] indole, 1H-dibenz [e, g] isoindole, naphtho [1,2,3_cd] indole, naphtho [L, 8-ef] Indole, naphtho [l, 8-fg] indole, naphtho [3, 2, 1-cd] indole, 1H-naphtho [l, 2-e] indole, 1H-naphtho [l , 2—f] Indole, 1H—naphtho [l, 2—g] indole,
- a fuel group condensed with a tricyclic heterocycle includes the above-mentioned fuel group condensed with a tricyclic heterocycle containing an optionally hydrogenated indole ring or isoindole ring.
- a phenyl group condensed with a tricyclic heterocycle exemplified below and a dihydro body, a tetrahydro body, a hexahydro body, an octahydro body, and a decahydro body are used.
- fluoranthene acephenanthrylene, aceanthrylene, triphenylene, pyrene, chrysene, naphthacene, praiadene, benzo [a] anthracene, indeno [1,2-a] indene, cyclopentene [a] phenanthrene, pyrido [1,, 2,: 1, 2] imidazo [4, 5—b] quinoxaline, 1H-2-oxapyrene, spiro [piperidine-1-4.9'-xanthene].
- ring E ', ring F' and ring G 'each represent a 5- to 9-membered heterocyclic heterocycle which may be substituted with an oxo group other than R 1 , and include ring A, ring F and ring G Oppo R 1 has the same meaning as above. ] And the like.
- Aryl group which may be substituted represented by Ar (2) condensed with a bicyclic heterocyclic ring which may have a substituent, or two identical or different monocyclic rings (at least Preferred examples of the case where Ar is a group represented by the following formula: when one of the rings is a monocyclic heterocyclic ring, and when condensed with (3) a tricyclic heterocyclic ring which may have a substituent.
- n represents an integer of 1 to 10.
- Preferred n is an integer of 1 to 6, particularly preferably 1 to 5, more preferably 2 to 5, particularly preferably 3, 4 or 5.
- R represents a hydrogen atom or a hydrocarbon group which may be substituted, and may be different when n is repeated.
- hydrocarbon group and “substituent” of the “optionally substituted hydrocarbon group” represented by R include the “hydrocarbon group” of the “optionally substituted hydrocarbon group” represented by R 1 above. It has the same meaning as “group” and "substituent”.
- R may be bonded to Ar or a substituent of Ar.
- R is preferably a hydrogen atom.
- Y represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group (preferably a nitrogen-containing saturated heterocyclic group) (Y is preferably a substituted heterocyclic group) Which may be an amino group].
- Y ′ represents an amino group which may be substituted.
- Examples of the “optionally substituted amino group” represented by Y and Y include, for example,
- R 4 and R 5 are the same or different and represent a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted acyl group, and R 4 and R 5 combine to form a ring You can do it. And the like are used.
- Examples of the “substituent” and “hydrocarbon group” of the “optionally substituted hydrocarbon group” represented by R and R 5 include, for example, the “optionally substituted hydrocarbon group” described in R 1 above. "Substituent” and "hydrocarbon group” are used.
- Preferred examples of the optionally substituted hydrocarbon group represented by R 4 and R 5 include, for example, 1 (i) a halogen atom (for example, fluoro, chloro, bromo, and odo), (ii) It has one to three substituents selected from lower alkoxy groups (for example, Ci- 6 alkoxy groups such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, etc.) and (iii) hydroxy groups.
- a halogen atom for example, fluoro, chloro, bromo, and odo
- It has one to three substituents selected from lower alkoxy groups (for example, Ci- 6 alkoxy groups such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, etc.) and (iii) hydroxy groups.
- alkyl group e.g., methyl, Echiru, flop Ropinore, isopropylidene Honoré, Puchinore, Isopuchinore, tert - Buchinore, sec - Buchinore, pen chill, to such cyclohexyl - 6 alkyl Group
- halogen atom e.g., methyl, Echiru, flop Ropinore, isopropylidene Honoré, Puchinore, Isopuchinore, tert - Buchinore, sec - Buchinore, pen chill, to such cyclohexyl - 6 alkyl Group
- halogen atom e.g., methyl, Echiru, flop Ropinore, isopropylidene Honoré, Puchinore, Isopuchinore, tert - Buchinore, sec - Buchinore, pen chill, to such cyclohexyl - 6
- lower alkoxy group e.g., main butoxy, ethoxy, n- Puropiruokishi, i one Puropiruokishi, n - such as C i _ 6 alkoxy group such Puchiruokishi
- a lower aralkyl group which may have 1 to 3 substituents selected from a hydroxy group and the like (for example, phenolene- 1 .
- alkynole for example, benzinole, feretinole, feninolepropyl, phenylbutyl
- phenylene Rupenchiru the phenyl hexyl, etc.
- naphthyl Chiru ⁇ - 6 alkyl e.g., alpha-naphthylmethyl, etc.
- C 1 _ 3 alkyl eg, diphenylmethyl, diphenylethyl, etc.
- C 7 _, 6 aralkyl group and the like are more preferable.
- C) Unsubstituted linear or branched lower alkyl group eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl) butyl, pentyl, etc.
- C i _ 6 alkyl groups such as cyclohexyl
- 2 unsubstituted lower Ararukiru group e.g., Hue - Lou -.
- alkyl e.g., base Njinore, Fueyunoreechiru, Hue - Norepuropinore, Fueninorebuchiru, Hue - Norepenchi Le, such as cyclohexyl phenyl
- Nafuchiru - 6 alkyl e.g., alpha-like naphthoquinone Chirumechiru
- Jifue two Lou C i _ 3 alkyl e.g., Jifue two Rumechi le, etc. Jifueniruechiru
- C such as 7 - 1 6 Ararukiru And the like.
- the “optionally substituted acyl group” represented by R 4 and R 5 for example, the “optionally substituted acyl group” described above for R 1 and the like can be used.
- R 4 and R 5 are bonded to each other to form a ring in the ⁇ optionally substituted amino group '' represented by Y and Y ′, that is, the ⁇ optionally substituted amino group '' represented by Y and Y ′
- a ⁇ good amino group '' represents a ⁇ cyclic amino group which may be substituted ''
- R 2 represents a hydrogen atom, an optionally substituted acyl group, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group
- p represents 1-3
- R ′ and R ′′ each represent a hydrogen atom or an optionally substituted alkyl group, and R ′ and R ′′ may be bonded to form a ring.
- R 2 represents a hydrogen atom, an optionally substituted acyl group, an optionally substituted V, a hydrocarbon group or an optionally substituted heterocyclic group
- R 2 represents a hydrogen atom, an optionally substituted acyl group, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group. A group represented by Which is preferably used.
- R 2 optionally substituted Ashiru group
- the "optionally substituted hydrocarbon group” and “optionally substituted heterocyclic group” is the above-mentioned R 1 Examples thereof include the same as the “optionally substituted acyl group”, “optionally substituted hydrocarbon group” and “optionally substituted heterocyclic group”.
- a nitrogen atom other than a carbon atom and two nitrogen atoms a nitrogen atom other than a carbon atom and two nitrogen atoms
- a preferred example is a 5- to 9-membered nitrogen-containing heterocyclic group (preferably nitrogen-containing saturated heterocyclic group) which may contain one heteroatom atom selected from an oxygen atom and a sulfur atom.
- a 5- to 9-membered nitrogen-containing heterocycle preferably nitrogen-containing saturated heterocycle
- nitrogen-containing heterocyclic group of the “optionally substituted nitrogen-containing heterocyclic group” represented by Y
- nitrogen-containing heterocyclic group in addition to a carbon atom and one nitrogen atom, for example, nitrogen atom, oxygen atom and sulfur
- a 5- or 9-membered nitrogen-containing heterocyclic group (preferably a nitrogen-containing saturated heterocyclic group) which may contain 1 to 3 heteroatoms such as atoms is used.
- These nitrogen-containing heterocyclic groups may be groups having a bond at a ring-constituting nitrogen atom or groups having a bond at a ring-constituting carbon atom. Examples of a group having a bond at the ring-forming nitrogen atom include, for example,
- Examples of the group having a bond at a ring-constituting carbon atom include, for example, a compound represented by the formula
- the ring Q 2 may contain, in addition to the carbon atom and one nitrogen atom, one or two heteroatoms selected from a nitrogen atom, an oxygen atom, a sulfur atom and the like, 5 to 9 members (Preferably a nitrogen-containing saturated heterocyclic group). And the like are used. More specifically, for example,
- the “substituent” of the “optionally substituted nitrogen-containing heterocyclic group (preferably nitrogen-containing saturated heterocyclic group)” represented by Y for example, the above R 2c and R 3c are formed together with the nitrogen atom in contact. Which may have a substituent.
- Substituent the represented by R 1 'which may be substituted hydrocarbon group, optionally substituted Ashiru group or an optionally substituted heterocyclic group "and the like are used.
- the substituents may be bonded to each other to form a ring, and specific examples of such a ring include a benzene ring and a 5- to 8-membered (preferably 5 to 6) Membered) aromatic monocyclic heterocycles (eg, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, virazole, 1,2,3_oxazidazole, 1,2,4-oxazidazole, 1,3,4
- a "optionally substituted cyclic amino group" as the “optionally substituted amino group” represented by Y and Y '; and a “optionally substituted nitrogen-containing heterocyclic group” represented by Y Has two or more substituents on one carbon atom
- the substituents may be bonded to each other to form a spiro ring.
- Specific examples of the case where such a spiro ring is formed include, for example, spiro (1H-indene-1,4, -piridinyl) ) Ring and the like.
- nitrogen-containing heterocyclic group of the "nitrogen-containing heterocyclic group which may be substituted" represented by Y, a 4-piperidinyl group, a 1-piperidinyl group or a 1-propylazyl group is exemplified. .
- R 6 has the same meaning as R 1 ], and the like are preferable.
- Y for example, the formula ——N NR 6 or 100′- R.
- R 6 is (i) C x _ 6 alkyl, - 6 alkoxy, halogen atom, nitro, mono- or di d - 6 alkyl Ichiriki Rubamoiruokishi, hydroxy, Shiano, carboxyl, C 1 one 6 alkoxycarbonyl, force Rubamoiru, cyclic ⁇ amino carbonyl, amino, Ji ⁇ - 6 alkyl Kano repo alkylsulfonyl ⁇ amino, Fuenirusuruho - Ruamino, ⁇ E - 6 alkylsulfonyl ⁇ amino, amidino, optionally substituted ureido or heterocyclic phenyl - C i - 6 alkyl (the Interview one 6 Al kill you Yopi ⁇ E one 6 alkoxy, force Rubamoiru, cyclic Aminokarubo -.
- Hue - shows 4 alkyl (such as methyl) Ureido, amidino, a dihydrothiazolyl or dihydroimidazolyl with optionally substituted downy Nji Le group - Le) sulfo Niruamino, Ureido, 3. ], And the like.
- R 6 is _ 4 alkyl (such as methyl), trihalogeno (such as fluoro) _ 4 alkyl (such as methyl), halogen atom (such as fluoro or chloro), nitro, hydroxy, carbamoyl ⁇ ⁇ , amino, amidino
- benzyl group which may be substituted with dihydroimidazolyl is preferable.
- the X 1 and X 2 At least one preferably represents NH.
- the divalent group represented by X may have a substituent at any position (preferably on a carbon atom).
- a strong substituent include lower (C x _ 6 ) alkyl
- cycloalkyl e.g., cyclopropyl, Shikuropuchi , Formyl, low-grade pentyl, cyclohexyl, cyclohexyl, etc.
- (C 2 _ 7 ) alkanols eg, acetyl, propionyl, butyryl, etc.
- lower — 6 ) lower alkoxy-monocarbonyl lower (C, — 6 ) lower alkoxy, hydroxyl, oxo and the like.
- the compounds represented by the formula (I) or salts thereof the compounds represented by the formula (II)
- R 1 represents a hydrogen atom, a hydrocarbon group which may be substituted or an acyl group which may be substituted;
- ring A represents a benzene ring which may further have a substituent;
- Y is substituted Represents an optionally substituted amino group.
- a salt thereof is preferably used.
- the salt of the compound having GPR14 antagonistic activity (including the compound represented by the formula (I) and the compound represented by the formula (II)) used in the present invention is a pharmacologically acceptable salt.
- Preferred salts include salts with inorganic bases, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids, and the like.
- the salt with an inorganic base include: alkaline metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; -Pum salt and the like.
- Preferred examples of the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N, -dibenzylethylenediamine. And salts with min.
- Preferred examples of the salt with an inorganic acid include, for example, salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
- salts with organic acids include, for example, formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p -Salts with toluenesulfonic acid and the like.
- Preferred examples of the salt with a basic amino acid include, for example, salts with arginine, lysine, ordinine, and the like.
- Preferred examples of the salt with an acidic amino acid include, for example, salts with aspartic acid, glutamic acid, and the like. Is mentioned.
- the compound having a GPR 14 antagonistic activity (including the compound represented by the formula (I) and the compound represented by the formula (II)) used in the present invention may be a hydrate, It may be a hydrate.
- the compound having a GPR 14 antagonistic activity used in the present invention (including the compound represented by the formula (I) and the compound represented by the formula (II))
- isomers configuration isomers
- diastereomers diastereomers
- conformers etc.
- the compound having a GPR 14 antagonistic activity (including the compound represented by the formula (I) and the compound represented by the formula (II)) used in the present invention is in a racemic form
- ordinary optical It can be separated into (S) -form and (R) -form by the dividing means, and each of the optically active form and the racemic form is included in the present invention.
- a compound having a GPR14 antagonistic activity or a salt thereof used in the present invention [including a compound represented by the formula, (I) or a salt thereof and a compound represented by the formula (II) or a salt thereof] [hereinafter, GPR14 antagonistic Sometimes referred to as medicine. ] May be used as a prodrug.
- prodrugs examples include compounds that convert to GPR14 antagonists by a reaction with an enzyme or gastric acid under physiological conditions in vivo, that is, enzymatically oxidize, reduce, or hydrolyze.
- GPR14 antagonist prodrugs include compounds in which the amino group of the GPR14 antagonist is acylated, alkylated, and phosphorylated (e.g., the amino group of the GPR14 antagonist is eicosanoylated, alanylated, pentyl) Aminocarponylation, (5-methyl-2-oxo-1,1,3-dioxolen-4-yl) methoxycarbonylation, tetrahydrofuranylation, pyrrolidylmethylation, viva- mouthyloxymethylylani, tert- Compounds in which the hydroxyl group of a GPR14 antagonist has been acylated, alkylated, phosphorylated, or borated (eg, the hydroxyl group of a GPR14 antagonist has been acetylated, palmitoylated, propanoylated, or vivaloyl) Compound, succinyl-dani, fumarylated, alkarylated,
- GPR14 antagonist prodrugs change to GPR14 antagonists under physiological conditions, as described in Hirokawa Shoten, 1990, ⁇ Development of Drugs, '' Volume 7, Molecular Design, pp. 163 to 198. It may be something.
- GPR14 antagonists isotope eg, 3 H, 14 C, 35 S, 125 I etc. targets, etc. It may be known.
- the GPR14 antagonist of the present invention can be used alone or in combination with a pharmaceutically acceptable carrier to produce a solid preparation such as tablets, capsenoles, granules and powders; or a liquid preparation such as syrups and injections. It can be administered orally or parenterally.
- Parenteral administration forms include, for example, injections, infusions, suppositories and the like.
- Pharmaceutically acceptable carriers include various organic or inorganic carrier materials commonly used as drug substances, such as excipients, lubricants, binders, and disintegrants in solid preparations; solvents and dissolution in liquid preparations. Formulated as auxiliaries, suspending agents, tonicity agents, buffers, soothing agents and the like. If necessary, additives for pharmaceutical preparations such as preservatives, antioxidants, coloring agents and sweeteners can also be used.
- excipients include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light caffeic anhydride and the like.
- Preferred examples of the lubricant include, for example, magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- Preferred examples of the binder include, for example, crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylsenorellose, polyvinylinopyrrolidone and the like.
- Preferable examples of the disintegrant include starch, canoleboxyl methylcellulose, canoleboxy methinoresenolerose kanoresum, croscarmellose sodium, carboxymethyl starch sodium and the like.
- the solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like.
- Preferred examples of the dissolution aid include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- the suspending agent include surfactants such as stearyltriethanolamine, sodium laurinole sulfate, laurylaminopropionic acid, lecithin, benzalcoium salt, benzethonium chloride, and glycerin monostearate; Polyvier alcohol, polyvinylpyrrolidone, carboxy methinoresenolerose sodium, methinoresenolerose, hydroxymethinoresenolerose, Examples include hydrophilic polymers such as hydroxyethyl cellulose and hydroxypropyl cellulose.
- the tonicity agent include sodium chloride, glycerin, D-mannitol and the like.
- Preferred examples of the buffer include buffers such as phosphate, acetate, carbonate, and citrate.
- Preferable examples of the soothing agent include benzyl alcohol and the like.
- Suitable examples of preservatives include, for example, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Preferred examples of the antioxidant include, for example, sulfite, ascorbic acid and the like.
- the compound represented by the formula (I) or a salt thereof can be produced by a method known per se. Further, the compound represented by the formula (I) or a salt thereof can be prepared, for example, by the following method, or the method described in EPA-4877071, EP-A-560235, WO 98/46590, WO 00/23437 or the like. It can be manufactured by a similar method.
- the compound used in each of the following production methods may form a salt similar to compound (I) as long as the reaction is not hindered.
- a protecting group generally used in peptide chemistry or the like is introduced into these groups.
- the target compound can be obtained by removing the protecting group as necessary after the reaction.
- Examples of the protecting group for the amino group include, but are not limited to, an optionally substituted _ 6 alkylcarbonyl (eg, acetyl, propionyl, etc.), formyl, phenylcarbonyl, and di- 6 alkyloxycarbonyl (eg, , main butoxycarbonyl, E Toki deer Lupo sulfonyl, such as t- script alkoxycarbonyl), Hue - Ruokishikaruboni Le (e.g., benz O propoxycarbonyl - Le etc.), c 7 - i. Aralkyloxy ball (for example, benzyloxy carbonate etc.), trityl, phthaloyl etc. Is used.
- an optionally substituted _ 6 alkylcarbonyl eg, acetyl, propionyl, etc.
- formyl e.g, acetyl, propionyl, etc.
- halogen atom for example, fluorine, chlorine, bromine, iodine, etc.
- C- 6 alkylcarbon for example, acetyl, propionyl, butyryl, etc.
- nitro group and the like are used. The number is about one to three.
- the protecting group of carboxyl group include the substituents have _ 6 may alkyl having a (e.g., methyl, Echiru, propyl, isopropyl, butyl, tert- butyl, etc.), phenyl, trityl and silyl.
- substituents include a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), di- 6- alkylcarbon (eg, acetyl, propioel, butyryl, etc.), formyl, nitro group, etc.
- the number of substituents is about 1 to 3.
- Ji for example may have a substituent ⁇ - 6 ⁇ alkyl (e.g., methyl, Echiru, propyl, isopropyl, butyl, tert- Bed chill etc.), Fueeru, C 7 - E .
- Aralkyl eg, benzyl, etc.
- 6- alkylcarbonyl eg, acetyl, propiole, etc.
- formyl phenoleoxycanoleponinole, C 7 —.
- aranolecyloxycarbonyl eg, benzyloxycarbonyl
- piral furanyl, silyl, etc.
- substituents include halogen atom (e.g., fluorine, chlorine, bromine, etc. ® ⁇ iodine), - 6 alkyl, phenyl, C 7 _ i. Aralkyl and nitro groups are used, and the number of substituents is about 1 to 4.
- halogen atom e.g., fluorine, chlorine, bromine, etc. ® ⁇ iodine
- - 6 alkyl phenyl
- Aralkyl and nitro groups are used, and the number of substituents is about 1 to 4.
- the removal method includes, for example, treatment with an acid, a base, reduction, ultraviolet light, hydrazine, phenolehydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate, etc. Is used.
- the compound (I) of the present invention and each of the starting compounds or synthetic intermediates may be an optical isomer, a stereoisomer, a positional isomer or a rotamer, or a mixture thereof. Included in compound (I) and starting compounds or intermediates for synthesis.
- the compound (I) may be a racemate or an optical isomer separated from the racemate. These can be isolated and purified according to a separation method known per se.
- the optical isomer can be produced according to a method known per se. Specifically, an optical isomer can be produced by using an optically active starting compound or a synthetic intermediate, or by optically resolving the racemate of the final compound according to a conventional method. .
- a method known per se for example, a fractional recrystallization method, an optically active column method, a diastereomer method and the like can be applied.
- Stereoisomers, positional isomers, and rotamers can also be produced by applying a method known per se. Each of the following reactions can be carried out without using a solvent or, if necessary, using an appropriate solvent.
- any solvent that can be generally used for a chemical reaction can be used as long as it does not hinder the reaction.
- examples thereof include hydrocarbon solvents (eg, hexane and toluene) and ether solvents.
- Solvents eg, ethyl ether, tetrahydrofuran, dioxane, dimethoxyethane
- amide solvents eg, formamide, N, N-dimethylformamide, N, N-dimethylacetamide, hexamethylphosphoric triamide
- Urea solvents for example, 1,3-dimethyl-2-imidazolidinone, etc.
- sulfoxide solvents for example, dimethylsulfoxide, etc.
- alcoholic solvents for example, methanol, ethanol, isopropanol, t- butanol, etc.
- Nitrile solvents eg, acetonitril, Organic solvents such as lopionitrile
- pyridine or water
- the amount of the solvent to be used is generally about 0.5 ml to about 10 O ml, preferably about 3 ml to about 30 ml, per 1 mmol of compound.
- the reaction temperature depends on the type of solvent used. Although different, it is usually about 130 ° C to about 180 ° C, preferably about 0 ° C to about 120 ° C.
- the reaction time varies depending on the reaction temperature, but is usually about 0.5 hour to about 72 hours, preferably about 1 hour to about 24 hours.
- the reaction is usually performed at normal pressure, but may be performed under pressurized conditions of about 1 atm to about 100 atm as needed.
- the “condensation reaction” can be performed in the presence of a base, if necessary.
- the base include inorganic salts such as sodium carbonate, sodium bicarbonate, carbonated lime, lithium carbonate, sodium hydroxide, hydroxylated lime, lithium hydride, sodium hydride, sodium methoxide, and potassium t-butoxide.
- Groups and organic bases such as pyridine, lutidine, collidine, and triethylamine are used.
- the amount of the base to be used is generally equimolar amounts to excess amounts, preferably about 1 to about 5 molar equivalents, relative to the conjugate.
- this reaction may be promoted in the presence of a catalytic amount of an iodide compound, for example, sodium iodide, potassium iodide, or 4-dimethinoleaminopyridine, if necessary.
- known compounds can be produced by the following synthesis methods. Further, it can be produced by the method described in JP-A-6-166676, JP-A-11-310532, EP-A-487071, EP-A-560235, WO 98/46590, WO 00/23437, or a method analogous thereto.
- novel compound of the present invention for example, the compound represented by the formula (II) or a salt thereof can be produced by the following synthesis method.
- step (aa) a compound represented by the formula (IIIa): wherein each symbol is as defined above.
- compound (Ilia) and a compound represented by the formula (I Va): wherein Z 1 is a leaving group, and other symbols are as defined above.
- compound (I Va) to produce compound (IIa).
- Examples of the leaving group represented by Z 1 include, for example, a halogen atom (for example, chloro, bromo, 3-and the like), a C, _ 6 alkylsulfonyloxy group (for example, methanesulfonyloxy, ethanesulfonyloxy, Trifluoromethanesulfur-oxy, etc.),
- arylsulfo-loxy group eg, benzenesulfo-loxy, p-toluenesulfonyloxy, etc.
- a halogen atom for example, bromo, odo, etc.
- the solvent for example, an alcohol solvent such as ethanol or a -tolyl solvent such as acetonitrile is preferably used.
- the reaction temperature varies depending on the type of the solvent used, but is preferably about 0 ° C to about 120 ° C.
- the reaction time varies depending on the reaction temperature, but is preferably about 1 hour to about 24 hours.
- the base for example, sodium carbonate, potassium carbonate, triethylamine and the like are preferably used.
- the amount of the base to be used is preferably about 1 equivalent to about 3 equivalents relative to compound (I Va).
- this reaction is promoted in the presence of a compound (I Va) in the presence of a catalytic amount of an iodide compound (eg, sodium iodide, potassium iodide, etc.) or 4-dimethylaminopyridine. Is also good.
- the reaction can be carried out in a solvent such as N, N-dimethylformamide or the like in the presence of a base such as carbon dioxide lime or sodium hydride.
- the amount of the base to be used is preferably about 1 equivalent to about 3 equivalents relative to compound (I Va).
- Compound (IVa) can be produced by a method known per se or a method analogous thereto.
- the starting compound (Ilia) or a salt thereof in the step (aa) can be produced, for example, according to the method described in WO 00/23437.
- the compound (IIb) — or the salt thereof, in which one X — is _NR 3 a — can be produced by the following reaction formula 2-1.
- step (ba) a compound represented by the formula (IIb): wherein each symbol is as defined above. (Hereinafter sometimes abbreviated as compound (IIb)) and compound (IVa) to produce compound (Ilb).
- the condensation reaction between compound (IIb) and compound (IVa) can be carried out in a solvent such as N, N-dimethylformamide in the presence of a base such as potassium carbonate or sodium hydride.
- the amount of the base to be used is preferably about 1 equivalent to about 3 equivalents relative to compound (IVa).
- the starting compound (IIb) or a salt thereof in the step (ba) can be produced by the following reaction formula 2-2. That is,
- compound (VI I lb) represented by the formula (IXb): wherein each symbol is as defined above.
- compound (I Xb) to produce compound (II lb).
- Compound (VIb) can be produced by nitrating compound (Vb) in step (bb).
- This reaction is carried out using a suitable nitrating reagent (for example, nitric acid, nitric acid, sulfuric acid, and tronium trifluoroborate) in a known manner (for example, synthesis).
- a suitable nitrating reagent for example, nitric acid, nitric acid, sulfuric acid, and tronium trifluoroborate
- the compound (VIlb) can be produced by a reduction reaction of the compound (VIlb).
- This reaction can be performed using an appropriate reduction reaction (for example, a catalytic reduction reaction using a transition metal catalyst, a reduction reaction using a metal such as tin in an acidic solvent, and the like).
- an appropriate reduction reaction for example, a catalytic reduction reaction using a transition metal catalyst, a reduction reaction using a metal such as tin in an acidic solvent, and the like.
- known methods for example, organic synthesis (Organic Synthesis), Coll. Vol. 5, 829-833 (1973), organic synthesis (Organic Synthesis)
- the compound (IIb) can be produced by a condensation reaction of the compound (VIIb) with the compound (IXb).
- the condensation reaction between the compound (VIlb) and the compound (IXb) can be carried out, for example, in the same manner as the condensation reaction between the compound (IIa) and the compound (IVa).
- the compound (IIIb) can be obtained by using a compound (VIIb) as a starting material, for example, by a reductive alkylation method (eg, Journal of the American Society). Chemical Society (J. Am. Chem. Soc.), 87, 2767 (1965), Organic Synthesis, Coll. Vol. 4, 283-285 (1963), etc.) or Michael addition reaction (For example, Helv. Chem. Acta, 43, 1898 (1960), Journal of Organic Chemistry (J. Org. Chem.), 39, 2044 (1974), Synthesis (Synthesis)). ), 5, 375 (1981)) or a method analogous thereto.
- a reductive alkylation method eg, Journal of the American Society. Chemical Society (J. Am. Chem. Soc.), 87, 2767 (1965), Organic Synthesis, Coll. Vol. 4, 283-285 (1963), etc.
- Michael addition reaction for example, Helv. Chem. Acta, 43, 1898 (1960), Journal of Organic Chemistry (J. Or
- the compound (lie) in which one X— is one NR 3 a CO— or a salt thereof can be produced by the following reaction formula 3.
- the compound (II lb) and the compound of the formula (IVc) are represented by the formula: wherein Z 2 is a leaving group, and other symbols are as defined above. (Hereinafter, sometimes abbreviated as compound (IVc)) to produce compound (lie).
- Examples of the leaving group represented by Z 2 a halogen atom (e.g. chlorine, bromine, Yodo) - 6 Arukiruokishi group (e.g., main butoxy, ethoxy, benzyl Okishi), C 6 - i.
- An aryloxy group for example, phenoxy, P -nitrophenoxy
- a halogen atom for example, chloro and the like
- a hydroxyl group and the like are preferably used.
- the amidation reaction between compound (IIIb) and compound (IVc) can also be performed using a suitable condensing agent or a base.
- a suitable condensing agent for example, a condensing agent generally used in the field of peptidylamide, in particular, dicyclohexylcarposimide, 1-ethyl-3- (3-dimethyla) Minopropyl
- This amidation reaction is carried out using carbodiimides and other carbodiimides, diphenylphosphoryl azides, phosphonic acids such as diethyl cyanophosphonate, and phosgene equivalents such as 1-1'-carbonylbis-1H- ⁇ f midazole. It can be performed.
- the amount of the condensing agent to be used is generally about 1 equivalent to about 5 equivalents, preferably about 1 equivalent to about 1.5 equivalents, per 1 mmol of compound (IIIb).
- Z 2 is a halogen atom
- an appropriate base for example, sodium carbonate, potassium carbonate, triethylamine and the like.
- the amount of the base to be used is generally about 1 equivalent-about 10 equivalents, preferably about 1 equivalent-about 2 equivalents, relative to compound (IIIb).
- one X- is one S-, one SO- or a S0 2 one, compound (II d) or a salt thereof, be prepared by the reaction equation 4-1 below Can be.
- the compound (IId) can be produced by performing a condensation reaction of the compound (IIId) and the compound (IVa) and, if necessary, subsequently performing an oxidation reaction.
- X d represents one S-, one SO- or one so 2- , and the other symbols have the same meanings as described above.
- the condensation reaction between compound (IIId) and compound (I Va) can be performed in a solvent such as N, N-dimethylformamide in the presence of a base such as sodium carbonate or sodium hydride. .
- a base such as sodium carbonate or sodium hydride.
- the amount of the base to be used is preferably about 1 equivalent to about 3 equivalents relative to compound (IVa).
- the compound (II d) in which X d is _S— can be converted to a compound (II d) in which x d is —so— or 1 so 2 — by performing an oxidation reaction as necessary.
- the oxidizing agent any one can be used as long as it is used as an oxidizing agent for a sulfide.
- metabenzo-perbenzoic acid, peracetic acid, hydrogen peroxide, alkali metal periodate and the like are used.
- perbenzoic acid and hydrogen peroxide are used.
- the amount of the oxidizing agent is particularly preferably about 1 equivalent to about 1.1 equivalent based on compound (IId).
- the starting compound (IIId) or a salt thereof in the step (da) can be produced by the following reaction formula 4-2. That is,
- step (db) the compound (Vb) is subjected to chlorosulfonylide to produce a compound (Vld).
- chlorosulfonic acid for example, chlorosulfonic acid, sulfinolechloride, sulfur dioxide monochloride and the like can be used. Particularly, chlorosulfonic acid and the like are preferable.
- the amount of the chlorosulfoelating reagent used is about 1 equivalent or a large excess.
- This reaction can be performed without a solvent or using a solvent.
- a solvent used in the case of using a solvent for example, dichloromethane, 1,2-dichloroethane, carbon disulfide and the like are preferable. Reactions without solvent are particularly preferred.
- the reaction temperature is preferably from about 120 ° C to about 100 ° C.
- chlorosulfonyl groups can be introduced at any of the reactable positions.
- position 7 is mainly chlorosulfonylated.
- compounds with a chlorosulfonylation at the 6-position can also be formed and separated.
- the compound (IId) can be produced by reducing the compound (VId).
- This reduction reaction can be carried out under appropriate reduction conditions, for example, a combination of a metal and an acid such as acetic acid and tin monohydrochloride, a catalytic reduction reaction using a transition metal catalyst, or a metal hydride such as a lithium hydride aluminum. It can. Particularly preferred is a reduction reaction using zinc monoacetic acid.
- reaction formula 5 (lie) or a salt thereof can be produced by the following reaction formula 5.
- the compound (VId) and a compound of the formula (IVe) are represented by the following formula: wherein each symbol is as defined above. (Hereinafter, sometimes abbreviated as “I-dye compound (IVe)”) to produce compound (l ie).
- the condensation reaction between the compound (VId) and the compound (IVe) can be performed, for example, in the same manner as the amidation reaction between the compound (IIb) and the compound (IVc).
- Compound (IVe) or a salt thereof can be produced by a method known per se or a method analogous thereto. For example, it can be produced by a method described in Journal of Medicinal Chemistry (J. Med. Chem.), 33, 1880 (1990) or a method analogous thereto.
- an alkali metal isocyanate (MOCN; M represents an alkali metal) is allowed to act on the compound (VI d), and then the compound (IV e) is allowed to react.
- Compound (II f) can be produced.
- This reaction can be produced, for example, by the method described in European Patent (EP-759431), JP-A-7-118267, or the like or a method analogous thereto.
- the reaction between the compound (V Id) and the alkali metal isocyanate is carried out in the presence of a base, if necessary.
- a base pyridine, triethylamine and the like are particularly preferable.
- the amount of the base to be used is preferably about 1 equivalent to about 5 equivalents relative to the compound (V Id).
- a reaction solvent particularly, acetonitrile and the like are preferably used.
- the alkali metal for example, potassium or the like is preferably used.
- step (g a) the compound (VI d) and a compound of the formula (IVg) [wherein each symbol is as defined above. (Hereinafter sometimes abbreviated as compound (I Vg)) to produce a compound (I Ig).
- the condensation reaction between the compound (Vld) and the compound (IVg) can be performed, for example, in the same manner as the amidation reaction between the compound (IIb) and the compound (IVc).
- Compound (IVg) can be produced using compound (IVe) by a method known per se or a method analogous thereto.
- a method of reacting compound (IVe) with S_methyl isothioprea for example, the method described in Journal of Organic Chemistry (J. Org. Chem.) 13, 924 (1948), etc.
- the method of action for example, Helvetica Himicaacta (Helv. Chem.
- Examples of the reagent used for the carbonyl group conversion reaction include reducing agents such as sodium borohydride, lithium aluminum hydride, and triethylsilane; organometallic reagents such as alkyl lithium and alkyl magnesium halide; and others, such as hydrogen cyanide. Are used.
- one CH (OH) one or one CH 2 carbonyl groups - Conversion to the sodium borohydride For example, lithium aluminum hydride, using a reducing agent such as Toryechirushiran, suitable reducing conditions (For example, a combination of triethylsilane-trifluoroacetic acid, lithium aluminum hydride monochloride aluminum, zinc monohydrochloride and the like).
- a reducing agent such as Toryechirushiran
- suitable reducing conditions for example, a combination of triethylsilane-trifluoroacetic acid, lithium aluminum hydride monochloride aluminum, zinc monohydrochloride and the like.
- This reaction can be performed, for example, by using Reduction with Complex Metal Hydrides Interscience, New York (1956), Chemicanore Society Review (Chem. Soc. Rev.), 5, 23 (1976), and Synthesis ( Synthesis), 633 (1974), J. Org. Chem. Soc.) 91, 2967 (1969), J. Org. Chem., 29, 29. 121
- Conversion of a carbinole group to one CR 3 c (OH) 1 can be carried out by using an organometallic reagent such as alkyl lithium or alkyl magnesium halide.
- organometallic reagent such as alkyl lithium or alkyl magnesium halide.
- the conversion of a carboxy group may be performed by a method described in Advanced Organic Chemistry, 5th ed. Wiley-interscience: New York, 1992, pp. 879-981, or a method analogous thereto. It can be carried out.
- step (ia) compound (IIIh) is reacted with an appropriate reagent. By converting the carbonyl group, the compound (IIi) can be produced.
- Examples of the conversion reaction of a carboninole group include a Wittig (Wiig) reaction, a Horner 1 ——Horner-Wadsworth-Emmons reaction, a Peterson-Olefinization reaction, and a Knebe reaction.
- a Nagel (Knoevenagel) reaction and the like can be mentioned, and as a reagent, a common reagent used in those reactions is used.
- the compound (IIh) can be reacted with an appropriate reagent to convert the carbonyl group to produce the compound (IIj).
- Examples of the reagent used for the conversion reaction of a carboxy group include substituted or unsubstituted hydrazine and optionally substituted hydroxyylamine.
- As the substituent Ji E one 6 alkyl group or the like is used.
- step (ka) the compound ( IIIh) is reacted with an appropriate reagent to convert the carbonyl group into a thiocarbonyl group, whereby (Ilk) can be produced.
- Examples of the reagent used for converting a carbonyl group to a thiocarbonyl group include general sulfurizing reagents such as Lawesson's reagent, diphosphorus pentasulfide, and hydrogen sulfide-hydrochloric acid.
- one X- is one C_ ⁇ _NR 3 a - those compounds (I Im) or a salt thereof can be prepared by the reaction equation 12 1 follows.
- step (ma) a compound represented by the formula (II Im): wherein each symbol is as defined above. (Hereinafter sometimes abbreviated as compound (II Im)) and compound (IVe) to produce compound (I Im).
- reaction between the compound (I Im) and the compound (IVe) can be carried out, for example, in the same manner as the amidation reaction between the compound (IIb) and the compound (IVc).
- the starting compound (II Im) in the step (ma) can be produced by the following reaction formula 12-2. That is, step (mb): acetylation reaction of compound (Vb), and step (mc): formula (Vim) wherein each symbol is as defined above.
- the compound (IIIm) can be produced by sequentially performing an oxidation reaction of a compound represented by the formula (hereinafter sometimes abbreviated as compound (Vim)) and, if necessary, a functional group conversion. it can.
- Reaction formula 12-2 Reaction formula 12-2
- the compound (Vb) can be acetylated to produce the compound (Vim).
- This reaction can be carried out under general Friedel-Crafts conditions.
- acetylation reagent acetyl chloride-acetic anhydride or the like is used. Specifically, for example, the method is described in JP-A-5-140149, JP-A-6-206875, Journal of Medicinal Chemistry (J. Med. Chem.), 37, 2292 (1994), etc. can do.
- the compound (II Im) By oxidizing the compound (Vim) in the step (mc), the compound (II Im), in particular, a compound in which Z 2 is a hydroxyl group can be produced.
- the oxidizing agent used in this reaction includes, for example, hypochlorite, hypobromite, or a simple halogen (eg, bromine, Iodine, etc.).
- hypochlorite e.g., hypobromite
- a simple halogen e.g, bromine, Iodine, etc.
- This reaction is specifically described in, for example, Org. Synthesis, Coll. Vol. 2, 428 (1943), Journal of the American Chemical Society (J. Am. Chem. Soc. ), 66, 894 (1944), etc., or a method equivalent thereto.
- a functional group of the compound is a hydroxyl group (II Im)
- Z 2 is a halogen atom (e.g. chlorine, bromine, Yodo)
- 6 Arukiruokishi group For example, methoxy, ethoxy, Benjiruokishi etc.
- C 6 - 1 It can be converted to a compound (II Im) which is an aryloxy group (for example, phenoxy, p-nitrophenoxy, etc.).
- the method of functional group conversion is described in, for example, Advanced Organic Chemistry, 5th ea. Wiley-Interscience ⁇ 'New York, 1992, pp.393-396,437-438, Comprehensive Organic Transformation (Comprehensive Organic Transformations), VCH Publishers Inc. (1989), etc., or a method based thereon.
- the compound (II) thus obtained can be isolated and purified by known separation and purification means, for example, concentration, concentration under reduced pressure, solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like.
- the compound having a GPR 14 antagonistic activity or a salt thereof (including the compound represented by the formula (I) or a salt thereof and the compound represented by the formula (II) or a salt thereof) according to the present invention has strong GPR 14 antagonistic activity. Therefore, it can be used as a drug that exhibits various vascular actions (for example, enhancement or suppression of vasoconstriction). Among them, a vasoconstriction inhibitor is preferably used.
- the compound of the present invention having GPR14 antagonistic activity or a salt thereof [the compound represented by the formula (I) or a salt thereof and the compound represented by the formula (II) or a salt thereof]
- a prophylactic / therapeutic agent for various diseases eg, cardiovascular diseases, etc.
- septic shock, etc. and especially as a preventive / therapeutic agent for ischemic myocardial infarction and congestive heart failure.
- the compound having a GPR 14 antagonistic activity or a salt thereof (including the compound represented by the formula (I) or a salt thereof and the compound represented by the formula (II) or a salt thereof) of the present invention has low toxicity. Can be used safely.
- the daily dose of the compound of the present invention having GPR14 antagonism or its salt varies depending on the condition and weight of the patient and the method of administration. In the case of oral administration, the adult (body weight 50 kg )
- the active ingredient per person [for example, the compound represented by the formula (II) or a salt thereof] is about 0.1 to 100 mg, preferably about 1 to 50 mg, and more preferably about 1 to 50 mg. 20 mg, given once or twice or three times a day.
- the compound of the present invention having a GPR 14 antagonistic activity or a salt thereof may be used with other drugs (particularly, , Hypertensive prophylactic and therapeutic agents, etc.).
- these drugs are formulated separately or simultaneously and mixed with a pharmacologically acceptable carrier, excipient, binder, diluent, etc., and administered orally or parenterally can do.
- a pharmacologically acceptable carrier excipient, binder, diluent, etc.
- parenterally can do.
- formulating drugs separately they can be administered separately by mixing them with a diluent or the like at the time of use.However, individual formulations prepared separately can be used simultaneously or with a time lag.
- kits for mixing and dispensing separately formulated products using a diluent at the time of use for example, mixing an ampoule containing individual powdered drugs with two or more drugs at the time of use
- Kit for injection which contains a diluent for dissolving the drug in the same subject
- kits for administering the individual preparations prepared separately and separately to the same subject simultaneously or separately with a time lag for example, put tablets containing individual drugs in the same or separate bags, and, if necessary,
- the pharmaceutical composition of the present invention also includes provided tablets kits for separately administering two or more tablets simultaneously or with a time lag, etc.).
- Antihypertensive drugs diuretics (eg, furosemide (Lasix), bumestat (Lunetron), azosemide (Diart), etc.), antihypertensive drugs (eg, ACE inhibitors, (enalapril maleate (Lenibase), delapril hydrochloride, etc.) and ⁇ Ca antagonists (manidipine, amlodipine, etc.), sperm or receptor blockers, etc .;
- Drugs for chronic heart failure cardiotonic drugs [eg, cardiac glycosides (digoxin, etc.),] 3 receptor stimulants (catecholamine preparations such as denopamine dipodbutamine) and PDE inhibitors, etc., diuretics [eg, furosemide De (Rasix), Spironolataton (Aldataton), etc.), ACEP and harmful drugs [eg, enalapril maleate (Lee base), etc.], Ca antagonists [eg, amlodipine, etc.] and; 8 receptor blockers, etc .; Drugs: disopyramide, lidocaine, chidin sulphate, flecainide acetate, mexiletine hydrochloride, amiodarone hydrochloride, and] 3 blockers, Ca antagonists, etc .; antithrombotic drugs: anticoagulants [eg, heparin sodium, Heparin calcium, perfurin calcium (perfurin), blood coagulation factor Xa inhibitor and coagulation Drug
- Coronary vasodilators diphedipine, diltiazem, nicorazil, nitric acid, etc .; cardioprotective drugs: openers for cardiac ATP-K, Na_H exchange inhibitors, endothelin antagonists, perotinsin antagonists, etc .;
- the synthetic DM used to screen cDNA encoding the human GPR14 protein is shown.
- the synthetic DNA used for screening of the cDNA encoding the human GPR14 protein is shown.
- Reference Example 1 Amplification of human GPR14 receptor cDNA by PCR using cDNA derived from human skeletal muscle
- Amplification by PCR was performed using human skeletal muscle-derived cDNA (Clontech) as the cycl form and synthetic DNA primers of SEQ ID NO: 1 and SEQ ID NO: 2.
- the synthetic DNA primer was constructed so that the gene in the region translated into the receptor protein was amplified.At this time, a nucleotide sequence recognized by the restriction enzyme Sal I was added to the 5 'side of the gene, and the 3' side was added. In order to add the nucleotide sequence recognized by the restriction enzyme Spe I to the 5 ′ side and the 3 ′ side, a recognition sequence of each restriction enzyme was added.
- the reaction mixture was composed of cDNA type 2.5 il, 0.2 ⁇ l each of synthetic DNA primers, 0.2 mM dNTPs, Advantage2 polymerase mix (Clontech) 11 and the buffer supplied with the enzyme. was set to 501.
- the cycle for amplification was performed using a thermal cycler (PerkinElmer), 95 ° C for 60 seconds, followed by 95 ° C for 30 seconds, 72 ° C for 3 minutes, and repeated 5 times. , 95 ° C ⁇ 30 seconds, 70 ° C ⁇ 3 minutes cycle 5 times, further, 95 ° C ⁇ 30 seconds, 68 ° C. 3 minutes cycle 20 times and finally 68 ° C ⁇ 3 Minutes of heating.
- the reaction product after PCR performed in Reference Example 1 was separated using a 0.8% low-melting point agarose gel, the band was cut out with a force razor, and DNA was obtained using GENECLEA SPIN (Bio 101). Was recovered. According to the prescription of Eukaryotic T0P0 TM TA Cloning kit (Invitrogen), the recovered DNA was cloned into a plasmid vector for animal cell expression-pcDNA3.1 / V5 / His to construct a plasmid pcDNA3.1-hGPR14 for protein expression.
- E. coli DH5a competent cell Toyobo
- clones containing the cDNA insert were selected on LB agar medium containing ampicillin and separated using a sterilized toothpick.
- a transformant E. coli DH5a / pcDNA3, 1-hGPR14 was obtained.
- Individual clones were cultured in LB medium containing ampicillin, and plasmid DNA was prepared using Quiawell 8 Ultra Plasmid kit (Qiagen). A portion of the prepared DNA was digested with the restriction enzyme SalI to confirm the size and orientation of the inserted receptor cDNA fragment.
- the reaction for determining the nucleotide sequence was carried out using a DyeDeoxy Terminator Cycle Sequence Kit (PerkinElmer) and decoded using a fluorescent automatic sequencer.
- the sequence of the obtained clone was analyzed, and a Sal I recognition sequence was added to the 5 side of the human GPR14 gene (EP 0 859 052 A1) sequence where all sequences were reported, and Spe was added to the 3 side. It was confirmed that the I recognition sequence matched the added gene sequence (SEQ ID NO: 3 and SEQ ID NO: 4).
- the nucleotide at position 1133 in the sequence of the human GPR14 gene of SEQ ID NO: 3 was G in the sequence determined in the present example as C in the report (EP 0859052 A1).
- the translated amino acids are the same for all bases.
- Plasmid DNA of hGPR14 was made the tone. Transfer this to CellPhect Transfection Kit (Amersham Was introduced into CHO dhfr-cells according to the attached protocol. 10 g of DNA was used as a suspension co-precipitated with calcium phosphate, and 24 hours before culturing was added to a 10 cm Petri dish seeded with 5 ⁇ 10 5 or 1 ⁇ 10 6 CHO dhfr-cells.
- An isotope-labeled human porcine tensin II for use in a binding inhibition experiment was prepared as follows. 5 g of human porcine tensin II (manufactured by Peptide Laboratories) is dissolved in 25 tl of 0.4 M sodium acetate (pH 5.6), and 200 ng of lactoperoxidase (Wako Pure Chemical Industries) is added thereto. after addition, [1 2 5 1] of 1 mCi - sodium iodide was added (Amersham off Alma shear Biotech) and 200 ng of hydrogen peroxide ( ⁇ ⁇ ⁇ ).
- Human GPR14-expressing CH0 cell membrane fraction was transferred to membrane dilution buffer (20 mM phosphate buffer). (pH 7.3), 150 mM NaCl, 5 mM MgCl 2 , 0.1% BSA, 0.05% CHAPS, 0.5raM PMSF, 0.1 g / ml Pepstatin, 20 ⁇ g / ml Leupeptin, 4 ⁇ g / ml E-64)
- membrane dilution buffer (20 mM phosphate buffer). (pH 7.3), 150 mM NaCl, 5 mM MgCl 2 , 0.1% BSA, 0.05% CHAPS, 0.5raM PMSF, 0.1 g / ml Pepstatin, 20 ⁇ g / ml Leupeptin, 4 ⁇ g / ml E-64)
- Microscint 20 (Packard kernel: h) was added, and radiation was performed. Activity was measured by Topcount (Packard). Specific binding is the value of total binding minus non-specific binding.
- the human GPR14 binding inhibitory activity of the test compound is represented by the ratio of the value obtained by subtracting the radioactivity of the cell membrane fraction to which the test compound was added from the total binding to the specific binding. The concentration at which the test compound inhibits the human GPR14 binding activity by 50% is shown.
- GPR14-expressing CH0 cells are seeded on a 96-well plate at 1 ⁇ 10 4 cells / well and cultured for 48 hours Then, the cells were washed with 0.1 ml of HBSS (hereinafter referred to as washing buffer) containing 20raM HEPES (pH 7.4), 1% FCS, 1% penicillin-streptomycin. Next, 100 ⁇ l of a washing buffer (hereinafter referred to as a reaction buffer) containing 4 ⁇ l Fluo3, 0.04% pluronic acid, and 2.5 mM probenicid was added, and the mixture was allowed to react at 37 ° C for 1 hour.
- washing buffer 20raM HEPES (pH 7.4)
- FCS 1% FCS
- penicillin-streptomycin 1% penicillin-streptomycin
- HPLC was measured under the following conditions ⁇ or ⁇ .
- Solvent Solution A; water containing 0.1% trifluoroacetic acid, solution B; acetonitrile containing 0.1% trifluoroacetic acid
- Solvent Solution A; water containing 0.1% trifluoroacetic acid, solution B; acetonitrile containing 0.1% trifluoroacetic acid
- MS mass spectrum
- Measuring device Mike Mouth Mass Platform II
- Solvent solution A; water containing 0.1% trifluoroacetic acid, solution B; acetonitrile containing 0.1% trifluoroacetic acid
- dichloromethane (1.5 ml) and water (1.5 ml), and the mixture was separated using a filter tube (Whatman; Power Tag No. 6984-0610).
- the dichloromethane solution was concentrated under reduced pressure.
- the residue was dissolved in methanol (1 ml), and 1M aqueous potassium carbonate solution (0.51 ml) was added. The mixture was stirred at room temperature for 1.5 hours. After distilling off methanol under reduced pressure, dichloromethane (1 ml) was added, and the mixture was separated using a filter tube (same as above).
- the dichloromethane solution was concentrated under reduced pressure, and the residue was purified by preparative HPLC to obtain the desired compound (24 mg).
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01949909A EP1310490A4 (en) | 2000-07-04 | 2001-07-04 | GPR14 ANTAGONIST |
AU2001271018A AU2001271018A1 (en) | 2000-07-04 | 2001-07-04 | Gpr14 antagonist |
US10/332,023 US20040063699A1 (en) | 2000-07-04 | 2001-07-04 | Gpr14 antagonist |
CA002414976A CA2414976A1 (en) | 2000-07-04 | 2001-07-04 | Gpr14 antagonistic agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000206865 | 2000-07-04 | ||
JP2000-206865 | 2000-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002002530A1 true WO2002002530A1 (fr) | 2002-01-10 |
Family
ID=18703723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/005784 WO2002002530A1 (fr) | 2000-07-04 | 2001-07-04 | Antagoniste de gpr14 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040063699A1 (ja) |
EP (1) | EP1310490A4 (ja) |
AU (1) | AU2001271018A1 (ja) |
CA (1) | CA2414976A1 (ja) |
WO (1) | WO2002002530A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6815451B2 (en) | 2001-03-27 | 2004-11-09 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
US7375227B2 (en) | 2001-12-04 | 2008-05-20 | Actelion Pharmaceuticals Ltd. | Quinoline derivatives |
EP2133340A1 (en) | 2002-12-20 | 2009-12-16 | Glaxo Group Limited | Novel benzazepine derivatives |
US7750161B2 (en) | 2003-09-26 | 2010-07-06 | Daniel Bur | Pyridine derivatives |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US8067601B2 (en) | 2004-10-12 | 2011-11-29 | Actelion Pharmaceticals Ltd. | 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt |
US11938134B2 (en) | 2017-03-10 | 2024-03-26 | Eikonizo Therapeutics, Inc. | Metalloenzyme inhibitor compounds |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741317B2 (en) * | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0487071A1 (en) * | 1990-11-22 | 1992-05-27 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
EP0560235A1 (en) * | 1992-03-09 | 1993-09-15 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic ketone derivatives, their production and use |
WO1998046590A1 (en) * | 1997-04-17 | 1998-10-22 | Takeda Chemical Industries, Ltd. | Thermogenic composition and benzazepine thermogenics |
WO2000023437A1 (fr) * | 1998-10-16 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant |
WO2000032627A1 (fr) * | 1998-11-30 | 2000-06-08 | Takeda Chemical Industries, Ltd. | Nouvelle substance physiologiquement active et ses procedes d'obtention et d'utilisation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA792042B (en) * | 1978-05-08 | 1980-05-28 | Scherico Ltd | Substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepines,process for the preparation thereof and pharmaceutical compositions containing them |
US4284555A (en) * | 1979-04-27 | 1981-08-18 | Schering Corporation | 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines |
US5462934A (en) * | 1992-03-09 | 1995-10-31 | Takeda Chemical Industries | Condensed heterocyclic ketone derivatives and their use |
US5851798A (en) * | 1997-01-27 | 1998-12-22 | Smithkline Beecham Corporation | Nucleic acid encoding human GPR14 receptor |
US6159700A (en) * | 1997-01-27 | 2000-12-12 | Smithkline Beecham Corporation | Method of finding agonist and antagonist to human and rat GPR14 |
WO2001018054A1 (en) * | 1999-07-23 | 2001-03-15 | Smithkline Beecham Corporation | Monkey gpr14 |
WO2001045694A1 (en) * | 1999-12-21 | 2001-06-28 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
EP1246619B1 (en) * | 1999-12-21 | 2004-10-20 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
JP2003518065A (ja) * | 1999-12-21 | 2003-06-03 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ii受容体アンタゴニスト |
US7229986B2 (en) * | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
US7091247B2 (en) * | 2000-06-28 | 2006-08-15 | Takeda Pharmaceutical Company Limited | Biphenyl compound |
-
2001
- 2001-07-04 US US10/332,023 patent/US20040063699A1/en not_active Abandoned
- 2001-07-04 CA CA002414976A patent/CA2414976A1/en not_active Abandoned
- 2001-07-04 AU AU2001271018A patent/AU2001271018A1/en not_active Abandoned
- 2001-07-04 EP EP01949909A patent/EP1310490A4/en not_active Withdrawn
- 2001-07-04 WO PCT/JP2001/005784 patent/WO2002002530A1/ja not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0487071A1 (en) * | 1990-11-22 | 1992-05-27 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
EP0560235A1 (en) * | 1992-03-09 | 1993-09-15 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic ketone derivatives, their production and use |
WO1998046590A1 (en) * | 1997-04-17 | 1998-10-22 | Takeda Chemical Industries, Ltd. | Thermogenic composition and benzazepine thermogenics |
WO2000023437A1 (fr) * | 1998-10-16 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant |
WO2000032627A1 (fr) * | 1998-11-30 | 2000-06-08 | Takeda Chemical Industries, Ltd. | Nouvelle substance physiologiquement active et ses procedes d'obtention et d'utilisation |
Non-Patent Citations (1)
Title |
---|
See also references of EP1310490A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6815451B2 (en) | 2001-03-27 | 2004-11-09 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists |
US7375227B2 (en) | 2001-12-04 | 2008-05-20 | Actelion Pharmaceuticals Ltd. | Quinoline derivatives |
EP2133340A1 (en) | 2002-12-20 | 2009-12-16 | Glaxo Group Limited | Novel benzazepine derivatives |
US7696193B2 (en) | 2002-12-20 | 2010-04-13 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
US7704994B2 (en) | 2002-12-20 | 2010-04-27 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
EP2186516A1 (en) | 2002-12-20 | 2010-05-19 | Glaxo Group Limited | Novel benzazepine derivative |
US7799773B2 (en) | 2002-12-20 | 2010-09-21 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
US8207331B2 (en) | 2002-12-20 | 2012-06-26 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
US7750161B2 (en) | 2003-09-26 | 2010-07-06 | Daniel Bur | Pyridine derivatives |
US8067601B2 (en) | 2004-10-12 | 2011-11-29 | Actelion Pharmaceticals Ltd. | 1-[2-(4-benzyl-4-hydroxy-piperidin-1 -yl )-ethyl]-3-(2-methyl-quinolin- 4-yl)- urea as crystalline sulfate salt |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US11938134B2 (en) | 2017-03-10 | 2024-03-26 | Eikonizo Therapeutics, Inc. | Metalloenzyme inhibitor compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1310490A1 (en) | 2003-05-14 |
EP1310490A4 (en) | 2004-03-17 |
AU2001271018A1 (en) | 2002-01-14 |
US20040063699A1 (en) | 2004-04-01 |
CA2414976A1 (en) | 2002-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001226269A (ja) | メラニン凝集ホルモン拮抗剤 | |
US6534496B1 (en) | Thermogenic composition and benzazepine thermogenics | |
AU758802B2 (en) | Drugs for improving vesical excretory strength | |
TW201219400A (en) | Compounds for treating neurodegenerative diseases | |
WO2002002530A1 (fr) | Antagoniste de gpr14 | |
EP0655451A1 (en) | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | |
AU2002367425B2 (en) | Preventives/remedies for urinary disturbance | |
WO2005000354A1 (ja) | 排尿障害予防・治療剤 | |
WO2002015934A1 (fr) | Agents prophylactiques et remedes contre des maladies du systeme nerveux central | |
FI85479C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla substituerade 11-//2-/(dietylamino) metyl/-1 -piperidinyl/-asetyl/5,11-dihydro-6h-pyrido/2,3-b//1,4/-bensodiazepin-6 -oner. | |
WO2001066143A1 (fr) | Agents vasoactifs | |
US20070232538A1 (en) | Uses of polypeptides | |
HU201759B (en) | Process for producing new condensed diazepinones and pharmaceutical compositions comprising same | |
JP2002097142A (ja) | Gpr14拮抗剤 | |
JPH07309835A (ja) | 四環式縮合複素環誘導体、その製造法および用途 | |
JPH11310532A (ja) | 熱産生促進剤 | |
JP2002138053A (ja) | 中枢神経系疾患予防・治療剤 | |
JP2007016039A (ja) | 排尿障害予防治療剤 | |
JP2003335701A (ja) | 排尿障害予防治療剤 | |
JP2006104208A (ja) | 排尿障害予防治療剤 | |
JP2001335576A (ja) | 三環式縮合複素環誘導体の結晶 | |
JP2002338491A (ja) | ポリペプチドの用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10332023 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2414976 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001949909 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001949909 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001949909 Country of ref document: EP |